| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Topline Data Readout example | Phase 1 | — | Subscribe to access the data. | CRISPR-Based Gene Editing Therapies | Endocrine System | ||
Topline Data Readout example | Phase 1 | — | Subscribe to access the data. | CRISPR-Based Gene Editing Therapies | Endocrine System | ||
Topline Data Readout example | Phase 1 | — | Subscribe to access the data. | CRISPR-Based Gene Editing Therapies | Endocrine System |
Recent Updates
Recently added Catalysts
Editas Medicine, Inc.$3.26
-0.16 (-4.85%)
D 33Pipeline Score Richly Valued Biotech · Commercial
Market Cap
270.22 M
EPS
-1.22
P/E Ratio
-
Value Trade
8.93 M
SEC Financials
Q1 2026Dilution Risk
35%Revenue
2.83 M
R&D Expenses
17.60 M
Operating CF
-23.06 M
Total Assets
149.34 M
Total Liabilities
144.93 M
Equity
4.41 M
D/E Ratio
12,345
-1.43 %
Week
-17.12 %
1 Month
54.19 %
3 Month
13.11 %
6 Month
-92.05 %
5 Year
-84.67 %
All Time
Cash Data
Cash Position
149.34 M
Monthly Burn
7.69 M
Runway
17.4 mo
Burn Trend
SEC Filing
May 5, 2026
Overview
Volume
3.59 M
52 Week Range
1.56 - 4.54
% held by Insiders
7.5 %
% held by Institutions
46.04 %
Enterprise Value
218.55 M
Total Shares
153.46 M
Short %
12.97 %
Float Shares
148.70 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Editas Medicine, Inc.
611Total events
10Upcoming
89Tier-1 (high impact)
2016 – 2027Coverage
Upcoming catalysts 10
Event history 601
Jun 11, 2026
Jun 4, 2026
Jun 2026
●IND SubmissionEDIT-401IND
Plan to submit CTN in Australia to TGA by mid-2026
Heterozygous Familial Hypercholesterolemiasource ↗
May 26, 2026
▼Equity OfferingCorporate
Pricing of underwritten public offering of common stock and warrants
May 26, 2026
▲FDA Feedback ReceivedEDIT-401FDA Meeting
Positive pre-IND feedback from FDA on nonclinical package, CMC plans, and study design
Heterozygous Familial Hypercholesterolemiasource ↗
May 25, 2026
◆Oral PresentationEDIT-401Presentation
Oral presentation at EAS Congress 2026: In vivo CRISPR gene editing upregulates LDLR and reduces LDL-C in non-human primates
hyperlipidemiasource ↗
May 24, 2026
May 14, 2026
◆Oral PresentationEDIT-401Presentation
Oral presentation at ASGCT 2026: Preclinical Development of EDIT-401
hyperlipidemiasource ↗
May 14, 2026
◆Poster PresentationEDIT-401Presentation
Poster presentation at ASGCT 2026: PK/PD of EDIT-401 in mice
hyperlipidemiasource ↗
May 14, 2026
▲Preclinical PoCEDIT-401Preclinical
Preclinical data: ≥90% mean LDL-C reduction in NHPs with single dose
hyperlipidemiasource ↗
Drug Pipeline Intelligence
D33
Pipeline Score $22M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.1x
rNPV / MCap Top 43%
Micro Cap (rank 520 of 911)
Percentile RankEditas Medicine, Inc. faces pipeline headwinds (33/100), with $355M risk-adjusted pipeline value, led by EDIT-301 in Sickle Cell Disease (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EDIT-301 Gene therapy | Sickle Cell Disease | Phase 1 | NCT04853576 | 57% | $355M | ACTIVE NOT_RECRUITING | 45 | SLOW | D (31) | Aug 1, 2025 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
reni-cel | sickle cell disease and beta thalassemia | — | 2025-06-12 | Editas Medicine's proprietary targeted lipid nanoparticle delivery achieved a mean of 58% HBG1/2 promoter editing in hematopoietic stem cells five months after a single intravenous dose, exceeding the ≥25% threshold necessary for therapeutic benefit in sickle cell disease and beta thalassemia. Read More | Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June Read More | |
reni-cel | sickle cell disease and beta thalassemia | — | 2025-06-12 | Editas Medicine's proprietary targeted lipid nanoparticle delivery achieved a mean of 58% HBG1/2 promoter editing in hematopoietic stem cells five months after a single intravenous dose, exceeding the ≥25% threshold necessary for therapeutic benefit in sickle cell disease and beta thalassemia. Read More | Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June Read More | |
reni-cel | sickle cell disease and beta thalassemia | — | 2025-06-12 | Editas Medicine's proprietary targeted lipid nanoparticle delivery achieved a mean of 58% HBG1/2 promoter editing in hematopoietic stem cells five months after a single intravenous dose, exceeding the ≥25% threshold necessary for therapeutic benefit in sickle cell disease and beta thalassemia. Read More | Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in EDIT
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
EDIT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
EDITEditas Medicine Announces Updated Presentation Time for Upcoming Investor Conference
Editas Medicine has announced an updated presentation time for its participation in the 2026 Jefferies Global Healthcare Conference. The presentation is scheduled for June 4, 2026, at 2:00 p.m. ET. The company aims to showcase its advancements in gene editing and its commitment to developing innovative therapies for serious diseases.
Read more →EDIT▲ +11.6%on this news· ran to +29% by day 1shared move
Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress
Editas Medicine presented promising preclinical data for EDIT-401 at the European Atherosclerosis Society Congress. The treatment achieved significant reductions in LDL-C, Lp(a), and ApoB in non-human primates, indicating its potential as a leading therapy for hyperlipidemia. The company plans to submit a Clinical Trial Notification by mid-2026 and aims for early human proof-of-concept data by the end of 2026.
Read more →EDIT▲ +11.6%on this news· ran to +29% by day 1shared move
Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering
Editas Medicine has announced a public offering of 55,555,556 shares at a price of $2.25 each, aiming to raise approximately $125 million. If all warrants are exercised, total proceeds could reach $319.4 million. The offering is expected to close on May 27, 2026, pending customary conditions. This move is part of Editas's strategy to fund its gene editing initiatives.
Read more →EDIT▲ +11.6%on this news· ran to +29% by day 1shared move
Editas Medicine Announces Proposed Public Offering
Editas Medicine has announced a proposed public offering of its common stock and accompanying warrants. The offering is managed by Cantor and Wells Fargo Securities and is subject to market conditions. The company aims to leverage its expertise in gene editing to develop innovative treatments for serious diseases. However, the completion and terms of the offering remain uncertain.
Read more →EDITEditas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting
Editas Medicine has presented new preclinical data for EDIT-401, indicating its potential as a one-time treatment for hyperlipidemia at the ASGCT 2026 Annual Meeting. The data showed a significant reduction of mean LDL-C by over 90% in non-human primates with a durable response lasting around 6 months. Additionally, the treatment demonstrated a promising safety profile without adverse effects at relevant doses. The findings also explore the potential of Editas' gene upregulation strategy for broader therapeutic applications.
Read more →EDITEditas Medicine Announces First Quarter 2026 Results and Business Updates
Editas Medicine (EDIT) announced its financial results for Q1 2026, highlighting advancements in EDIT-401, a gene editing therapy targeting hyperlipidemia. The company aims to achieve early human proof-of-concept data by the end of 2026. Despite recent positive preclinical results, including significant LDL-C reduction, Editas faces challenges, including reaffirmed patent decisions that may hinder its CRISPR technology. Overall, while the outlook for EDIT-401 remains optimistic, financial losses and revenue declines present areas of concern.
Read more →EDIT▲ +5.9%on this news
Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences
Editas Medicine announced that five abstracts have been accepted for presentation at upcoming scientific conferences, showcasing new preclinical data on EDIT-401. This gene editing therapy aims to lower LDL cholesterol levels and may offer a transformative treatment for hyperlipidemia. Presentations will occur at the ASGCT Annual Meeting, TIDES USA Conference, and EAS Congress.
Read more →EDITEditas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference
Editas Medicine announced that the U.S. Patent and Trademark Office reaffirmed a previous decision favoring the Broad Institute in a patent interference case regarding CRISPR/Cas9 technology. This decision reinforces Broad's inventorship priority for gene editing in human cells. Editas holds exclusive licenses for these patents, supporting its development of innovative gene editing therapies.
Read more →EDIT▲ +16%on this news· ran to +32% by day 1
Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates
Editas Medicine reported its financial results for Q4 and full year 2025, highlighting significant progress with its lead candidate, EDIT-401, which showed over 90% LDL-C reduction in preclinical studies. The company is preparing for an IND/CTA submission by mid-2026 and aims to initiate a first-in-human trial for HeFH patients. Despite a strong cash position, the company reported increased net losses for the year.
Read more →EDIT▲ +5.6%on this news· ran to +22% by day 3
Editas Medicine to Participate in Upcoming Investor Conferences
Editas Medicine, a leader in gene editing, will participate in several investor conferences in March 2026. The company's management aims to engage with investors and share insights into their innovative pipeline. Editas is committed to developing CRISPR-based therapies for serious diseases, showcasing their advancements in the field.
Read more →EDITGenflow Biosciences PLC Announces Directorate Change
Genflow Biosciences has appointed Gad Berdugo as the new Independent Non-Executive Chairman. This strategic move aims to enhance the company's focus on gene therapies for age-related diseases. Berdugo brings over 30 years of experience in biotechnology and corporate development, which is expected to accelerate Genflow's R&D efforts and global presence.
Read more →EDITEditas Medicine Announces Third Quarter 2025 Results and Business Updates
Editas Medicine reported strong third quarter results for 2025, highlighting promising preclinical data for its lead candidate, EDIT-401, which demonstrated over 90% reduction in LDL cholesterol in non-human primates. The company is on track to submit an IND/CTA for EDIT-401 by mid-2026 and aims to achieve initial human proof-of-concept data by the end of 2026. Additionally, Editas has extended its cash runway into the third quarter of 2027, ensuring continued development of its therapies.
Read more →EDITEditas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025
Editas Medicine announced a moderated digital poster presentation of EDIT-401 at the American Heart Association (AHA) Scientific Sessions 2025. The event will take place from November 7-10 in New Orleans, Louisiana. The accepted abstract is available on the AHA website, and the poster will be accessible on Editas' website during and after the event.
Read more →EDITEditas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress
Editas Medicine has reported promising preclinical proof-of-concept data for EDIT-401, a gene therapy aimed at reducing LDL cholesterol. At the ESGCT Congress, the company highlighted that EDIT-401 achieved over 90% mean reduction in LDL-C in non-human primate studies. This innovative approach could greatly benefit individuals with high LDL cholesterol levels.
Read more →EDITEditas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences
Editas Medicine announced an oral presentation at the European Society of Gene and Cell Therapy Congress in Seville, Spain, scheduled for October 7-10, 2025. The presentation will be accessible on their website post-event. Additionally, the company will participate in various investor conferences throughout October, enhancing their visibility in the market.
Read more →EDITEditas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate
Editas Medicine has nominated EDIT-401 as its lead in vivo development candidate, targeting LDL cholesterol reduction. The therapy demonstrated approximately 90% LDL-C reduction in non-human primates and aims for human proof-of-concept data by the end of 2026. The company maintains a strong cash position to support its operations into 2027.
Read more →EDITEditas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate
Editas Medicine will host a webinar on September 2, 2025, to announce its lead in vivo development candidate. The event will be accessible live and archived on the company's website. Editas focuses on developing transformative gene editing medicines for serious diseases using CRISPR technology.
Read more →EDITEditas Medicine Announces Second Quarter 2025 Results and Business Updates
Editas Medicine reported its Q2 2025 results, highlighting the selection of a lead development candidate expected in September, with plans to file an IND by mid-2026. The company showed strong cash reserves of $178.5 million, enough to sustain operations until mid-2027. They celebrated achievements in their collaboration with Bristol Myers Squibb and presented promising preclinical data. However, they faced significant losses and restructuring charges related to discontinued programs.
Read more →EDIT▲ +7.4%on this news
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June
Editas Medicine announced promising results from its proprietary targeted lipid nanoparticle delivery system, achieving 58% mean editing of the HBG1/2 promoter in hematopoietic stem cells in non-human primates. This approach shows potential for treating sickle cell disease and beta thalassemia. The data will be presented at the European Hematology Association Congress in Milan.
Read more →EDIT▼ -6.1%on this news
Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June
Editas Medicine announced that new data from preclinical studies in non-human primates has been accepted for presentation at the EHA 2025 Congress. The data demonstrates therapeutically relevant gene editing levels and a favorable biodistribution profile, supporting the development of their proprietary HSC-tLNP for treating sickle cell disease and beta thalassemia. The presentation will take place on June 14, 2025, in Milan, Italy.
Read more →EDIT▼ -8%on this newsshared move
Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas’ Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting
Editas Medicine presented new in vivo data at the ASGCT Annual Meeting, showing significant levels of HBG1/2 promoter editing in hematopoietic stem cells using their targeted lipid nanoparticle strategy. The studies illustrate editing levels up to 48% in humanized mice and 47% in non-human primates, exceeding therapeutic thresholds for treating sickle cell disease and beta thalassemia. Promising biodistribution results indicate reduced liver targeting, bolstering the approach's safety profile and efficacy. The company is focused on advancing this preclinical success towards clinical applications.
Read more →EDITEditas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting
Editas Medicine reported promising in vivo proof of concept data at the ASGCT meeting, demonstrating a potential treatment for an undisclosed liver target. The results showed a significant reduction of a disease-associated biomarker and high efficiency in editing the target gene using lipid nanoparticles. Notably, around 70% editing and over 80% biomarker reduction were achieved in mice. This progress suggests a transformative therapeutic approach, with more information expected later this year.
Read more →EDIT▲ +6.2%on this newsshared move
Editas Medicine Announces First Quarter 2025 Results and Business Updates
Editas Medicine announced its first quarter 2025 results, highlighting advancements in CRISPR-based in vivo gene editing. The company is set to present preclinical data at both the ASGCT conference and TIDES USA 2025, demonstrating potential breakthroughs in gene therapy. Despite reporting a net loss of $76.1 million, Editas maintains a strong cash position expected to last until mid-2027. Additionally, the company plans to declare two in vivo gene editing development candidates by mid-2025.
Read more →EDIT▲ +6.2%on this newsshared move
Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board
Editas Medicine announced that the U.S. Court of Appeals affirmed parts of a previous decision regarding Patent Trial and Appeal Board proceedings related to CRISPR patents. The court remanded the case back for further review, but noted that Editas's in-licensed patents for CRISPR/Cas12a are not affected by this decision. The company remains focused on its strategy to license its intellectual property and develop gene editing medicines, expressing confidence in the value of its IP portfolio.
Read more →EDIT▼ -6.1%on this news· ran to -19% by day 1
Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May
Editas Medicine, Inc. has announced that it will release its financial results for the first quarter of 2025 on May 12 through press release and SEC filings. The company will not hold quarterly financial results conference calls in the future. Additionally, management is set to participate in the Bank of America Global Healthcare Conference on May 13, where they will engage in a fireside chat in Las Vegas, NV.
Read more →EDITEditas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
Editas Medicine announced the acceptance of five abstracts, including one oral presentation, at the 28th Annual Meeting of the American Society of Gene and Cell Therapy. The preclinical data being presented focuses on their in vivo gene editing pipeline, showcasing innovative approaches such as lipid nanoparticles for gene delivery. The findings demonstrate significant progress in their drug development efforts aimed at serious diseases. This presentation highlights Editas's commitment to enhancing gene editing outcomes through advanced techniques and methodologies.
Read more →EDITEditas Medicine Announces Chief Financial Officer Transition
Editas Medicine has announced that Chief Financial Officer Erick J. Lucera will step down effective March 28, 2025, to pursue a new opportunity. Amy Parison, the Senior Vice President of Finance, has been appointed as the new CFO. Parison has been with Editas for two and a half years and is expected to leverage her experience to enhance the company's focus on developing in vivo gene editing medicines. The transition reflects the company's commitment to internal talent development and growth in their financial leadership.
Read more →EDIT▲ +16.5%on this news
Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates
Editas Medicine reported its fourth quarter and full-year 2024 financial results, highlighting significant advancements in its gene editing platform, particularly in vivo gene editing via gene upregulation. The company is on track to declare two in vivo editing candidates in mid-2025 and has demonstrated promising preclinical data across several tissues. However, it also announced the termination of its reni-cel program and associated workforce reductions due to a lack of commercial partnership prospects. Financially, the company experienced increased net losses compared to the previous year.
Read more →EDITEditas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March
Editas Medicine plans to announce its fourth quarter and full year 2024 financial results on March 5, 2025, through press release and SEC filings. The company will not hold quarterly conference calls moving forward. Additionally, management will participate in several investor conferences in March, including events by TD Cowen, Leerink Partners, and Barclays. These activities reflect the company's commitment to keeping investors informed about its progress and innovations in gene editing.
Read more →EDIT▼ -7.9%on this news
Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities
Editas Medicine has announced significant advancements in its gene editing research, including successful in vivo preclinical proof of concept data demonstrating hematopoietic stem cell (HSC) editing in non-human primates. The company outlined key milestones anticipated for 2025, such as the declaration of two development candidates and further progress on its in vivo pipeline. Editas aims to submit an investigational new drug application and reach human clinical trials by 2026. The company's financial stability, with substantial cash reserves, extends into mid-2027, positioning it well for future developments.
Read more →EDIT▲ +6.7%on this news
Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Editas Medicine, a leader in gene editing, has announced that its President and CEO, Gilmore O'Neill, will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025. The conference will take place in San Francisco, California, and a live webcast of the presentation will be available on the company's website. This presentation will highlight Editas Medicine's advancements in CRISPR technology and its potential impact on treating serious diseases.
Read more →EDIT▼ -5%on this news· ran to -28% by day 1
Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years
Editas Medicine is making a strategic transition to become a fully in vivo gene editing company, with plans to achieve human proof of concept within two years. Recent advancements in CRISPR-edited medicines have prompted this shift, particularly successes in editing hematopoietic stem cells and liver tissues. However, the company will be discontinuing its reni-cel project due to an unsuccessful search for a commercial partner, leading to a significant workforce reduction. This move is part of broader cost-saving measures aimed at extending the company's operational runway until mid-2027.
Read more →EDITEditas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting
Editas Medicine presented updated clinical data from the RUBY trial at the ASH Annual Meeting, showcasing the efficacy and safety of reni-cel in treating patients with severe sickle cell disease. The data demonstrated significant increases in total hemoglobin and fetal hemoglobin levels, with the majority of patients remaining free from vaso-occlusive events post-treatment. Patients reported meaningful improvements in pain and overall quality of life, despite two serious adverse events occurring. Overall, the trial's outcomes suggest a promising profile for reni-cel as a durable treatment option.
Read more →EDITEditas Medicine Announces Third Quarter 2024 Results and Business Updates
Editas Medicine reported its third quarter 2024 results, announcing significant progress in its gene editing programs. The company achieved in vivo preclinical proof of concept for HBG1/2 editing and plans to present updates from the RUBY trial for sickle cell disease at the upcoming ASH Annual Meeting. Financially, Editas secured $57 million through a licensing agreement, but also reported a net loss of $62.1 million, highlighting ongoing financial challenges. Future updates on pipeline developments are anticipated in early 2025.
Read more →EDIT▼ -12.5%on this news
Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update
Editas Medicine has announced significant progress toward its 2024 goals, including achieving in vivo preclinical proof of concept for hematopoietic stem and progenitor cell editing. This milestone is seen as a major step towards developing a novel treatment for sickle cell disease and beta thalassemia. The company is also exploring opportunities to partner or out-license its product, reni-cel, to streamline resource allocation towards its in vivo pipeline. Editas is set to present further data and strategic updates in an upcoming company-sponsored webinar.
Read more →EDIT▲ +11.9%on this newsshared move
Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics
Editas Medicine and Genevant Sciences have established a collaboration to develop novel mRNA-LNP gene editing therapeutics, focusing on two undisclosed targets. This agreement allows Editas to utilize Genevant's lipid nanoparticle technology alongside its own CRISPR Cas12a systems. Genevant stands to receive up to $238 million in upfront and milestone payments, alongside tiered royalties on sales. Both companies are optimistic about the potential impact of their combined technologies on future gene editing treatments.
Read more →EDITEditas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept
Editas Medicine, Inc. will hold a webinar on October 22, 2024, to provide updates on their progress towards 2024 goals, including the achievement of preclinical proof of concept for in vivo applications. The webinar will also cover business development and financial updates, which are crucial for stakeholders. This event underscores the company's ongoing efforts in gene editing and its commitment to addressing serious diseases through innovative treatments.
Read more →EDITEditas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust
Editas Medicine has announced a monetization financing deal with DRI Healthcare Trust, securing an upfront payment of $57 million in exchange for future license fees related to its Cas9 gene editing technology licensed to Vertex Pharmaceuticals. This non-dilutive capital is intended to support the company's ongoing pipeline development and strategic objectives. The deal also allows Editas to retain rights to certain fixed annual license fees and contingent payments from Vertex. This partnership signals a positive step in Editas' efforts to advance its clinical-stage projects.
Read more →EDIT▼ -12.2%on this news
Editas Medicine Announces Second Quarter 2024 Results and Business Updates
Editas Medicine announced its financial results for the second quarter of 2024, highlighting significant progress in clinical trials, particularly with its lead product reni-cel for sickle cell disease. The company is on track to present additional data from the RUBY and EdiTHAL trials by the end of the year, and it holds a strong financial position with funding extended into 2026. While there's positive momentum, the company reported an increased net loss compared to the previous year and reduced collaboration revenues.
Read more →EDITEditas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update
Editas Medicine, a clinical-stage gene editing company, announced a conference call for August 7, 2024, to discuss its second quarter results for 2024 and provide a corporate update. The call will allow shareholders and interested parties to gain insights into the company's progress and pipeline. Editas highlights its commitment to developing CRISPR-based therapies for serious conditions, showcasing its role in the evolving gene editing market.
Read more →EDIT▼ -7.8%on this news
Document Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress All patients t
Editas Medicine has reported promising new safety and efficacy data from the RUBY trial of renizgamglogene autogedtemcel (reni-cel) in 18 patients with sickle cell disease. All patients treated in the trial experienced normalization of total hemoglobin levels and significant improvements in fetal hemoglobin. The safety profile of reni-cel was consistent with existing treatments, with no serious adverse events reported. Results will be presented at the EHA Annual Congress, indicating ongoing developments in gene therapy for sickle cell disease.
Read more →EDIT▼ -7.8%on this news
Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress
Editas Medicine has released new safety and efficacy data from the RUBY trial concerning its gene-edited therapy, reni-cel, used to treat patients with sickle cell disease. The data, presented at the European Hematology Association Annual Congress, indicates positive outcomes, including normalization of hemoglobin levels and absence of vaso-occlusive events in all patients treated. The trial demonstrated that reni-cel was well-tolerated with no serious adverse events reported to date, supporting its potential as a durable treatment for this condition.
Read more →EDIT▼ -7.8%on this news
Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress
Editas Medicine has reported new safety and efficacy data from the EdiTHAL clinical trial for reni-cel, an investigational therapy for transfusion-dependent beta thalassemia. All seven patients treated maintained hemoglobin levels above the transfusion threshold and were transfusion-free following treatment. Reni-cel demonstrated a well-tolerated safety profile consistent with existing myeloablative conditioning therapies. These findings suggest reni-cel may provide significant clinical benefits to individuals suffering from this condition.
Read more →EDITEditas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June
Editas Medicine announced that two abstracts detailing clinical data from the RUBY and EdiTHAL trials of renizgamglogene autogedtemcel (reni-cel) have been accepted for presentation at the European Hematology Association Congress in June 2024. The RUBY trial involves patients with severe sickle cell disease, while the EdiTHAL trial includes patients with transfusion-dependent beta thalassemia. Key findings from these trials will be shared, highlighting efficacy and safety data. The results are anticipated to further support the therapeutic potential of reni-cel as a game-changing treatment for these conditions.
Read more →EDITEditas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
Editas Medicine presented preclinical data showcasing advancements in their in vivo gene editing pipeline at the ASGCT annual meeting. Key developments include the first application of AsCas12a in vivo and optimized lipid nanoparticle delivery systems. The research also identified RNA guide modifications that improve gene editing efficiency. Furthermore, data demonstrated a decrease in intraocular pressure in a mouse model of primary open angle glaucoma, marking a significant step toward confirming in vivo proof of concept by the end of 2024.
Read more →EDIT▼ -11.4%on this newsshared move
Editas Medicine Announces First Quarter 2024 Results and Business Updates
Editas Medicine reported significant progress in its Phase 1/2/3 RUBY clinical trial for severe sickle cell disease with completed adult cohort enrollment and additional adolescent patients. The company is on track to present clinical data for both the RUBY and EdiTHAL trials in mid-2024. Financially, Editas maintains a strong position, projecting operational funds into 2026, despite a reported increase in net loss and decreased R&D revenues in Q1 2024 compared to the same period last year. The firm also highlights its advancements in in vivo gene editing technologies and collaboration extensions with Bristol Myers Squibb.
Read more →EDITEditas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events
Editas Medicine, Inc. has announced that it will host a conference call on May 8, 2024, to discuss its first quarter results and provide a corporate update. The company will also participate in several investor conferences throughout May, including the Bank of America Health Care Conference and the RBC Capital Markets Global Healthcare Conference. Editas aims to leverage CRISPR technology to develop innovative treatments for serious diseases. Recordings of the events will be available on their website following each conference call.
Read more →EDITEditas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
Editas Medicine has announced a two-year extension of its collaboration with Bristol Myers Squibb, focusing on the development of alpha-beta T cell medicines for cancer and autoimmune diseases. The partnership includes 13 opted-in programs across 11 gene targets, with several initiatives already in advanced stages. The collaboration, which initially began in 2015, now potentially extends to 2028, highlighting both companies' commitment to innovative therapies. Editas is set to benefit from milestone payments and royalties as developments progress.
Read more →EDITEditas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
Editas Medicine has announced the acceptance of three abstracts for presentation at the upcoming American Society of Gene and Cell Therapy Annual Meeting. Among the presentations will be pre-clinical data demonstrating advanced gene editing capabilities using lipid nanoparticle technology and AsCas12a modifications. The findings aim to enhance in vivo gene editing outcomes and hold potential for treating serious diseases. The company is looking to establish in vivo proof of concept by the end of the year, although there are inherent uncertainties in their research progress.
Read more →EDIT▲ +24.9%on this news
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates
Editas Medicine reported its financial results for the fourth quarter and full year 2023, highlighting its progress in clinical trials and collaborations. The company is on track to present additional data from the RUBY and EdiTHAL trials in 2024. Recent partnerships, particularly with Vertex Pharmaceuticals, are expected to enhance financial stability. Despite some increases in net losses and expenses, Editas maintains a strong operational outlook.
Read more →EDITEditas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events
Editas Medicine, Inc. has announced a conference call on February 28, 2024, to discuss their fourth quarter and full year 2023 results. This call will provide a corporate update along with insights into their pipeline of precision genomic medicines. The company will also participate in several key investor conferences throughout March 2024, indicating active engagement with the investment community.
Read more →EDITEditas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference
Editas Medicine announced its anticipated milestones and strategic priorities for 2024 at the J.P. Morgan Healthcare Conference. The company aims to present clinical data updates for reni-cel and initiate the adolescent cohort in the RUBY trial. Additionally, they plan to establish in vivo preclinical proof-of-concept for an undisclosed indication and continue sublicensing their foundational intellectual property. With a solid financial position, Editas is positioned for continued growth in gene editing and commercialization efforts.
Read more →EDIT▼ -5.1%on this newsshared move
Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Editas Medicine, Inc. has announced that its President and CEO, Gilmore O'Neill, will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024. The event will take place in San Francisco, CA, and a live webcast will be available for viewers. Editas is a clinical-stage genome editing company, dedicated to developing treatments using CRISPR technologies for serious diseases. The archived presentation will be accessible for approximately 30 days after the event.
Read more →EDIT▲ +5.7%on this news
Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9
Editas Medicine and Vertex Pharmaceuticals have entered into a non-exclusive license agreement for Editas's Cas9 gene editing technology, specifically targeting the BCL11A gene to develop treatments for sickle cell disease and beta thalassemia. This partnership will allow Vertex to utilize Editas's innovative gene editing capabilities, extending their potential to address unmet medical needs. Notably, the agreement ensures that Editas Medicine's financial resources are bolstered and extended into the year 2026, providing a more stable runway for their ongoing projects.
Read more →EDIT▲ +5.7%on this news
availability and timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expecta
Editas Medicine has entered into a non-exclusive license agreement with Vertex Pharmaceuticals for the use of its Cas9 gene editing technology, specifically for targeting the BCL11A gene related to sickle cell disease and beta thalassemia. This partnership extends Editas' financial resources into 2026, likely enhancing its capacity to advance its pipeline. The Cas9 technology holds promise for precise gene editing, potentially addressing significant unmet medical needs in the hematologic disorder space.
Read more →EDIT▼ -5.7%on this newsshared move
President and Chief Medical Officer, Editas Medicine. "I would like to thank the clinical trial participants, their families, clinicians, and colleagues at collaborating institutions that contribute to the RUBY and EdiTH
Editas Medicine announced positive new safety and efficacy data for EDIT-301, now known as renizgamglogene autogedtemcel (reni-cel), in its RUBY and EdiTHAL clinical trials. All patients treated in the RUBY trial, which focuses on severe sickle cell disease, achieved normal hemoglobin levels and were free from vaso-occlusive events. The company reported no serious adverse events related to the treatment, highlighting its well-tolerated nature. The results indicate a promising potential for reni-cel as a durable therapy for patients living with severe sickle cell disease and transfusion-dependent beta thalassemia.
Read more →EDIT▼ -5.7%on this newsshared move
Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar
Editas Medicine has announced new safety and efficacy data on EDIT-301, now known as renizgamglogene autogedtemcel (reni-cel), during the American Society of Hematology (ASH) Annual Meeting. In the RUBY and EdiTHAL trials involving 17 patients, all RUBY patients showed no vaso-occlusive events post-infusion and maintained normal hemoglobin levels. The treatment was well-tolerated and indicated promising effects, including an early and significant increase in hemoglobin levels. Further clinical updates are anticipated in 2024, highlighting the potential of reni-cel in treating severe sickle cell disease and beta-thalassemia.
Read more →EDIT▲ +18.2%on this news
Editas Medicine Announces Third Quarter 2023 Results and Business Updates
Editas Medicine has reported its third quarter 2023 results along with significant business updates. The company anticipates sharing clinical data from the RUBY trial for sickle cell disease and the EdiTHAL trial for beta thalassemia at the upcoming ASH Annual Meeting. Editas has also strengthened its executive team by appointing Caren Deardorf as the first Chief Commercial and Strategy Officer. Furthermore, the FDA granted EDIT-301 Regenerative Medicine Advanced Therapy designation, underscoring its potential in treating serious hematological conditions.
Read more →EDITEditas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar
Editas Medicine announced that clinical data from the RUBY and EdiTHAL trials of EDIT-301 will be presented at the ASH 2023 Annual Meeting and in a company-sponsored webinar. The data highlights the safety and efficacy of EDIT-301 in treating patients with severe sickle cell disease and transfusion-dependent beta thalassemia. The company expresses optimism regarding the potential of EDIT-301 to offer life-changing benefits based on the results so far. The webinar and presentation details have been scheduled for December 11, 2023.
Read more →EDITEditas Medicine Announces Third Quarter 2023 Results Conference Call and Upcoming Investor Events
Editas Medicine, a clinical-stage genome editing company, announced a conference call scheduled for November 3, 2023, to discuss its third quarter results and provide corporate updates. Additionally, the company will participate in investor conferences, including Stifel 2023 Healthcare Conference and Evercore ISI's Annual HealthCONx Conference later in November. This highlights Editas's strategy to maintain investor relations and share its progress in the genome editing sector.
Read more →EDITEditas Medicine Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EDIT-301 for the Treatment of Severe Sickle Cell Disease
Editas Medicine has announced that the FDA has granted its investigational gene editing therapy EDIT-301 RMAT designation for the treatment of severe sickle cell disease. This designation is aimed at expediting the development and review processes for promising regenerative medicine therapies. EDIT-301 aims to provide a one-time, durable treatment benefit by editing a patient's own stem cells to increase fetal hemoglobin production. The company plans to share further clinical updates regarding the RUBY trial by year-end.
Read more →EDIT▼ -9.5%on this news
Editas Medicine Reports Inducement Grants to New Chief Commercial and Strategy Officer
Editas Medicine has announced the appointment of Caren Deardorf as the new Chief Commercial and Strategy Officer. In conjunction with her appointment, the company granted her stock options to acquire up to 123,350 shares at a price of $8.00 per share. The stock options vest over four years, highlighting the company's commitment to attracting top talent for its leadership team. Editas Medicine is focused on developing CRISPR-based treatments for serious diseases.
Read more →EDIT▼ -9.5%on this news
Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer
Editas Medicine announced the appointment of Caren Deardorf as its first Chief Commercial and Strategy Officer. Deardorf, with over 25 years in biotechnology, will lead the company's commercial organization and strategy, particularly focusing on the commercialization of EDIT-301 for sickle cell disease. Her experience includes previous roles at Magenta Therapeutics and Biogen, where she notably contributed to major product launches. This strategic move aims to enhance Editas' capabilities in bringing its pipeline products to market.
Read more →EDITEditas Medicine Announces Upcoming Investor Events
Editas Medicine, Inc., a clinical-stage genome editing company, has announced its participation in several upcoming investor conferences, including the Wells Fargo Healthcare Conference and the Morgan Stanley 21st Annual Global Healthcare Conference. Management will engage in fireside chats at these events, enhancing the company's visibility within the healthcare investment community. Investors can view the live webcasts of these presentations on the company's website, with archived replays available for 30 days afterward. This initiative underscores Editas Medicine's ongoing efforts to establish a robust relationship with investors.
Read more →EDIT▲ +5.7%on this news
Editas Medicine Announces Second Quarter 2023 Results and Business Updates On track to dose 20 total patients in the EDIT-301 RUBY trial for SCD and provide a clinical update by year-end Commenced parallel patient dosing
Editas Medicine reported its second quarter 2023 results, highlighting progress in its clinical trials for sickle cell disease (SCD) and beta thalassemia. The company is on track to dose 20 patients in the EDIT-301 RUBY trial, with a clinical update anticipated by the end of the year. Financially, Editas reported increased cash reserves, ensuring funding through 2025. The appointment of new executives is expected to enhance the company's operational capabilities as it advances towards commercialization of its therapies.
Read more →EDITEditas Medicine and Azzur Group Expand Partnership to Accelerate Editas’ Manufacturing Capabilities for Advancing the EDIT-301 Program Through Approval to Commercialization
Editas Medicine and Azzur Group have expanded their partnership to enhance the manufacturing capabilities for EDIT-301, an experimental therapy for severe sickle cell disease and transfusion-dependent beta thalassemia. The new agreement, which includes compliant cleanroom space and laboratory services, aims to accelerate the clinical supply and support the advancement of the EDIT-301 program towards commercialization. Azzur's new facility in Devens, expected to open in early 2024, is set to further bolster these efforts. Editas has utilized Azzur's services since 2020, emphasizing the importance of this partnership in achieving their mission.
Read more →EDITEditas Medicine Announces Second Quarter 2023 Results Conference Call and Corporate Update
Editas Medicine, Inc. announced that it will host a conference call on August 2, 2023, to discuss its second quarter 2023 financial results and provide a corporate update. The call will be accessible to U.S. and international callers and will also be available via webcast on the company's website. This event underscores Editas' ongoing commitment to advancing its pipeline of genome editing therapies.
Read more →EDITEditas Medicine Reports Inducement Grant to New Chief Scientific Officer
Editas Medicine has appointed Linda C. Burkly, Ph.D. as its new Chief Scientific Officer and granted her an inducement award. This includes stock options for up to 135,500 shares at a price of $8.66 per share, which will vest over a period of four years. The grant is intended to incentivize Dr. Burkly in her new role, aligning her interests with those of the company and its shareholders. Editas Medicine specializes in genome editing for serious diseases, leveraging CRISPR technologies.
Read more →EDITEditas Medicine Strengthens Executive Leadership Team with Appointment of Linda C. Burkly, Ph.D., as Chief Scientific Officer
Editas Medicine has appointed Linda C. Burkly, Ph.D., as the new Chief Scientific Officer. Burkly, who brings over 35 years of experience in biotechnology, will lead the company's drug discovery team and manage activities related to its pipeline of experimental medicines. Her background includes significant contributions to the development of approved drugs, which positions her to drive Editas' objectives in programmable in vivo gene editing. The company aims to develop differentiated gene editing therapies for serious diseases, thereby enhancing its potential for technical, regulatory, and commercial success.
Read more →EDIT▼ -16.3%on this news· ran to -28% by day 3
Editas Medicine Announces Pricing of Offering of Common Stock
Editas Medicine has announced the pricing of its underwritten offering of 12,500,000 shares of common stock at $10.00 per share, with expected gross proceeds of about $125 million. The transaction is set to close on or about June 20, 2023, pending customary conditions. Leading financial institutions, including J.P. Morgan Securities, Cowen and Company, and Evercore Group, are managing the offering. Editas is a clinical-stage genome editing firm focused on developing treatments using CRISPR-based technologies.
Read more →EDITEditas Medicine Announces Offering of Common Stock
Editas Medicine has announced an underwritten public offering of common stock to raise approximately $125 million, with an additional option for underwriters to purchase up to $18.8 million more shares. The offering is being managed by J.P. Morgan Securities, Cowen, and Evercore. However, the success of the offering is subject to market conditions, and there is no guarantee of completion or specific terms. The company focuses on developing genome-editing therapies and has filed a registration statement with the SEC for this offering.
Read more →EDITEditas Medicine Announces Positive Initial EDIT-301 Safety and Efficacy Data from the First Four Patients Treated in the RUBY Trial and the First Patient Treated in the EdiTHAL Trial EDIT-301 was well-tolerated and demon
Editas Medicine reported positive initial safety and efficacy data from the RUBY trial for EDIT-301, a treatment for sickle cell disease. The first four patients treated showed significant improvements in hemoglobin levels, maintaining normal levels and fetal hemoglobin increases. No serious adverse events were noted, indicating a satisfactory safety profile. Additionally, the results from the EdiTHAL trial are reportedly consistent with those observed in the RUBY trial, further supporting the potential of EDIT-301 as a treatment option.
Read more →EDIT▲ +8.6%on this newsshared move
Editas Medicine to Host Virtual Event to Discuss EDIT-301 Clinical Data from the RUBY Trial for Severe Sickle Cell Disease and the EDITHAL Trial for Transfusion-dependent Beta Thalassemia
Editas Medicine is set to host a virtual event on June 12 to discuss clinical data from the RUBY trial for EDIT-301, aimed at treating severe sickle cell disease, and from the EDITHAL trial for transfusion-dependent beta thalassemia. Key highlights will include initial safety and efficacy results from a select number of patients in both trials, which will provide insights into the performance of this experimental treatment. This event follows a presentation at the European Hematology Association's congress, emphasizing the ongoing research and development efforts by Editas in genome editing therapies.
Read more →EDITEditas Medicine Reports Inducement Grant to New Chief Financial Officer
Editas Medicine has announced the appointment of Erick Lucera as its new Chief Financial Officer. In conjunction with this appointment, the Board granted him an inducement stock option award allowing the purchase of 155,800 shares at $9.61 each. The stock options will vest over a four-year period, starting with 25% vesting after one year of employment. This move is part of Editas Medicine's efforts to advance its genomic medicine pipeline.
Read more →EDITEditas Medicine Announces Appointment of Erick J. Lucera as Chief Financial Officer
Editas Medicine has appointed Erick J. Lucera as the new Chief Financial Officer, effective May 17, 2023, succeeding Michelle Robertson. Lucera brings over 30 years of experience in financial management within the life sciences sector. The transition is poised to support Editas's aim of delivering innovative medicinal treatments and preparing for future regulatory steps. Robertson will remain in an advisory role until August 16, 2023, to ensure a smooth handover.
Read more →EDITEditas Medicine to Present Clinical Data from the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease at the EHA 2023 Congress
Editas Medicine has announced that clinical data from the RUBY trial of EDIT-301 for severe sickle cell disease will be presented at the EHA 2023 Congress. The oral presentation will cover efficacy and safety data based on multiple patients. The company is making progress in its clinical development and anticipates further updates later this year, including dosing 20 patients in the trial by year-end.
Read more →EDIT▲ +12%on this news
Editas Medicine Announces First Quarter 2023 Results and Business Updates Company to provide a clinical update on the EDIT-301 Phase 1/2 RUBY trial for SCD in June at the European Hematology Association Congress (EHA) an
Editas Medicine reported its Q1 2023 results, highlighting key advancements in clinical trials, particularly the EDIT-301 RUBY trial for sickle cell disease. The company plans to dose 20 patients by year-end and has successfully dosed the first patient in the EDITHAL trial, marking progress in two significant clinical programs. New leadership appointments aim to strengthen the company’s strategic direction as it seeks to establish itself in the gene editing field. Financially, Editas has sufficient liquidity to operate through 2025.
Read more →EDITEditas Medicine Announces Publication in Nature Biotechnology of Comprehensive SLEEK Gene Editing Technology Data
Editas Medicine announced the publication of data regarding its SLEEK gene editing technology in Nature Biotechnology. The SLEEK technology allows for high knock-in efficiency of multiple clinically relevant transgenes, addressing a significant challenge in the gene editing field. This innovative approach leverages the AsCas12a nuclease, achieving over 90% efficiency in various target cells. The potential applications of SLEEK in generating effective cell therapies, particularly in oncology, were highlighted by the research's success in producing robust NK cells in animal models.
Read more →EDITEditas Medicine Announces First Quarter 2023 Results Conference Call and Upcoming Investor Events
Editas Medicine, a clinical-stage genome editing company, has announced a conference call scheduled for May 5, 2023, to discuss its first quarter 2023 results and provide corporate updates. The call will be accessible via phone and webcast. Furthermore, management will participate in two upcoming investor conferences in May, facilitating investor engagement and communication about their pipeline and developments.
Read more →EDITEditas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Sickle Cell Disease
Editas Medicine has announced that the FDA granted Orphan Drug Designation to its gene editing therapy, EDIT-301, for treating sickle cell disease. This designation emphasizes the urgent need for new treatment options for this condition, which significantly impacts patients’ quality of life. EDIT-301 is also being studied in the RUBY trial, which aims to assess its safety and efficacy in patients with severe sickle cell disease. The company anticipates sharing clinical data updates from this trial later in the year.
Read more →EDIT▲ +20.3%on this news
Editas Medicine Strengthens Board of Directors with Appointment of New Chair and New Director
Editas Medicine has appointed Emma Reeve as the new Chair of the Board, effective at the next annual stockholder meeting on June 1. Reeve, who has been an Independent Director since September 2021, replaces James C. Mullen. Additionally, Elliott Levy, M.D., has joined the Board as an Independent Director, bringing over 20 years of experience in biopharmaceutical research and development. These appointments are anticipated to enhance Editas' strategic direction as it transitions into a commercial company focused on gene editing therapies.
Read more →EDITEditas Medicine Strengthens Executive Leadership Team with Appointment of Linea Aspesi as Chief People Officer
Editas Medicine has appointed Linea Aspesi as its new Executive Vice President and Chief People Officer. Aspesi brings over 25 years of experience, including significant roles in the life sciences sector, and will lead the company's human resources and people strategy. The appointment is part of Editas' broader strategy to accelerate growth and enhance its organizational culture, aligning with its mission to develop transformative genomic medicines. Asserting the importance of its talent, Editas aims to inspire its team for future advancements in healthcare.
Read more →EDIT▲ +6.2%on this news
Editas Medicine Announces Fourth Quarter and Full Year 2022 Results and Business Updates Commenced parallel patient dosing in the EDIT-301 RUBY trial for SCD, following clinical proof-of-concept demonstrated last quarter
Editas Medicine has reported its fourth quarter and full year 2022 results, announcing significant milestones including the commencement of patient dosing in the EDIT-301 RUBY trial for sickle cell disease (SCD) and the initiation of the EDIT-301 EDITHAL trial for transfusion-dependent thalassemia (TDT). The company is also on track to provide a clinical update for the RUBY trial by mid-2023. Despite a notable net loss of $60.7 million in Q4, Editas continues to maintain a cash runway expected to support operations through 2025, as it aims to position itself as a leader in programmable in vivo gene editing.
Read more →EDITEditas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2022 Results and Corporate Update
Editas Medicine, a clinical-stage genome editing company, will host a conference call on February 22, 2023, to discuss its fourth quarter and full year 2022 financial results and provide a corporate update. The conference will allow participants to engage directly with the company's leadership regarding its strategic advancements in genome editing using CRISPR technologies. Additionally, the event will highlight the company’s pipeline and vision for transformative genomic medicines.
Read more →EDITEditas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline to Acquire Editas’ iNK Cell Franchise and Related Gene Editing Technologies
Editas Medicine has entered a definitive agreement to license its iNK cell franchise and gene editing technologies to Shoreline Biosciences. This deal includes an exclusive license for the SLEEK technology and the acquisition of Editas's preclinical iNK programs, including EDIT-202. The transaction aims to allow Editas to focus its resources on in vivo gene editing medicine development while Shoreline enhances its portfolio of immunotherapies. The agreement also entails upfront and milestone-based payments for Editas.
Read more →EDIT▼ -8.7%on this news
Editas Medicine Announces Strategic Updates and Portfolio Reprioritization
Editas Medicine has announced a strategic update emphasizing a narrowed focus on hemoglobinopathies and in vivo gene editing, leading to a reduction of workforce by about 20% to extend its cash runway into 2025. The company will discontinue internal investments in inherited retinal diseases and iNK programs, seeking partnerships for further development. The Chief Scientific Officer, Mark S. Shearman, will step down by March 31, 2023. The strategic shift aims to enhance the likelihood of success for the company's remaining clinical programs.
Read more →EDIT▲ +9.5%on this newsshared move
Editas Medicine to Present at the 41st Annual J.P. Morgan Healthcare Conference
Editas Medicine, Inc. has announced that its President and CEO, Gilmore O'Neill, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023. The event will take place in San Francisco, CA, and a live webcast of the presentation will be available on the company's website. The conference presentation signifies the company's continued progress in genome editing and its commitment to transparency with investors.
Read more →EDITEditas Medicine Announces Positive Safety and Efficacy Data from the First Two Patients Treated in the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease EDIT-301 was well-tolerated and demonstrated a
Editas Medicine Announces Positive Safety and Efficacy Data from the First Two Patients Treated in the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease EDIT-301 was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning
Read more →EDIT▼ -5.1%on this newsshared move
Editas Medicine to Host Virtual Event to Highlight Initial Clinical Data from the RUBY Trial of EDIT-301 for Severe Sickle Cell Disease
CAMBRIDGE, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a live webinar on, Tuesday, December 6, at 8:00 a.m. ET to present initial clinical data from the Phase 1/2 RUBY tr
Read more →EDIT▼ -10.1%on this news
Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial EDIT-101 demonstrates a favorable safety profile across all dose cohorts Preliminary efficacy signals of
Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial EDIT-101 demonstrates a favorable safety profile across all dose cohorts Preliminary efficacy signals of consistent improvement in BCVA plus additional efficacy en
Read more →EDITEditas Medicine Announces Third Quarter 2022 Results and Business Updates Dosed second patient with EDIT-301 in the Phase 1/2 RUBY trial for sickle cell disease On track to announce initial preliminary clinical data from
Editas Medicine Announces Third Quarter 2022 Results and Business Updates Dosed second patient with EDIT-301 in the Phase 1/2 RUBY trial for sickle cell disease On track to announce initial preliminary clinical data from RUBY trial by year-end Completed cell editing and curren
Read more →EDITEditas Medicine to Host Conference Call Discussing Third Quarter 2022 Results and Corporate Update
CAMBRIDGE, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that it will host a conference call and webcast on Wednesday, November 2, 2022, at 8:00 a.m. ET to provide a corporate update and res
Read more →EDITEditas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the European Society of Gene and Cell Therapy Annual Meeting
Studies in non-human primates demonstrated nearly 100% gene editing and knockout of endogenous RHO gene and more than 30% replacement protein levels using a dual vector AAV approach Treated eyes showed morphological and functional photoreceptor preservation EDIT-103 advancing t
Read more →EDIT▲ +13.4%on this news
Editas Medicine Announces Second Quarter 2022 Results and Business Updates Appointed Baisong Mei, M.D., Ph.D., Chief Medical Officer, strengthening senior leadership team Achieved successful engraftment of first patient
Editas Medicine Announces Second Quarter 2022 Results and Business Appointed Baisong Mei, M.D., Ph.D., Chief Medical Officer, strengthening senior Achieved successful engraftment of first patient treated with EDIT-301 for sickle cell disease; first clinical use of Editas-engin
Read more →EDITEditas Medicine Announces Clinical Achievements in the Development of EDIT-301 for Sickle Cell Disease
Successful engraftment of first patient dosed with EDIT-301 for sickle cell disease FDA removed partial clinical hold for the RUBY trial in EDIT-301 First clinical use of Editas-engineered AsCas12a enzyme Initial clinical data from the RUBY trial expected by year-end CAMBRIDG
Read more →EDITEditas Medicine to Host Conference Call Discussing Second Quarter 2022 Results and Corporate Updates
CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Wednesday, August 3, 2022, at 8:00 a.m. ET to provide financial results and corporate upd
Read more →EDITEditas Medicine Reports Inducement Grant to New Chief Medical Officer
CAMBRIDGE, Mass., July 20, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the grant of an inducement award to the Company’s newly appointed Chief Medical Officer, Baisong Mei, M.D., Ph.D. In connection with Dr. Mei
Read more →EDITEditas Medicine Appoints Baisong Mei, M.D., Ph.D., as Chief Medical Officer
CAMBRIDGE, Mass., July 18, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the appointment of Baisong Mei, M.D., Ph.D., as the Company’s Senior Vice President and Chief Medical Officer, effective immediately. Dr. Me
Read more →EDITEditas Medicine Reports Inducement Grants to New Chief Executive Officer
CAMBRIDGE, Mass., June 06, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the grant of inducement awards to the Company’s newly appointed President and Chief Executive Officer, Gilmore O’Neill, M.B., M.M.Sc. As pre
Read more →EDIT▼ -7.8%on this news
Editas Medicine Presents Data on SLEEK Gene Editing Technology at the American Society of Gene and Cell Therapy Annual Meeting
SLEEK results in highly efficient multi-transgene knock-in and enables tunability of transgene expression Double knock-in iNK cells demonstrate strong tumor killing effect and prolonged in vivo persistence in an ovarian cancer mouse model CAMBRIDGE, Mass., May 18, 2022 (GLOBE N
Read more →EDIT▲ +7.8%on this news· ran to +18% by day 1
Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Beta Thalassemia
CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to EDIT-301, an investigational, gene editing medicine, for
Read more →EDIT▲ +11.5%on this news· ran to -22% by day 3
Editas Medicine Announces First Quarter 2022 Results and Business Updates Appointed Gilmore O'Neill as CEO effective
Editas Medicine Announces First Quarter 2022 Results and Business Updates Appointed Gilmore O'Neill as CEO effective June 1, 2022; James C. Mullen to serve as Executive Chairman First pediatric patient dosed in Phase 1/2 BRILLIANCE trial of EDIT-101 for LCA10; clinical data upd
Read more →EDIT▲ +11.5%on this news· ran to -22% by day 3
Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the Association for Research in Vison and Ophthalmology Conference
Studies in non-human primates demonstrated nearly 100% gene editing knockout of endogenous RHO gene and more than 30% replacement protein levels Treated eyes showed morphological and functional photoreceptor preservation EDIT-103 advancing towards IND-enabling studies CAMBRIDG
Read more →EDIT▲ +7.8%on this newsshared move
Editas Medicine to Present Pipeline and Platform Data Demonstrating Progress Towards Developing Transformative Gene Editing Medicines at the American Society of Gene and Cell Therapy Annual Meeting
CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that four abstracts have been accepted for presentation, including three oral presentations, at the 25th Annual Meeting of the American Socie
Read more →EDITEditas Medicine to Host Conference Call Discussing First Quarter 2022 Results and Corporate Update
CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Wednesday, May 4, 2022, at 8:00 a.m. ET to provide a corporate update and results for th
Read more →EDIT▼ -6.9%on this newsshared move
Editas Medicine Receives FDA Rare Pediatric Disease Designation for EDIT-301 for the Treatment of Beta Thalassemia
CAMBRIDGE, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease designation to EDIT-301, an investigational, gene-edited me
Read more →EDIT▼ -11.2%on this news
Editas Medicine Appoints Gilmore O’Neill as Chief Executive Officer
James C. Mullen to Serve as Executive Chairman CAMBRIDGE, Mass., April 14, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that its Board of Directors has appointed Dr. Gilmore O’Neill, M.B., M.M.Sc., as President
Read more →EDITEditas Medicine Announces Dosing of First Pediatric Patient in the BRILLIANCE Clinical Trial of EDIT-101 for LCA10
Marks the first-ever in vivo delivery of an experimental CRISPR gene editing medicine to a pediatric patient Company on track to complete dosing of the pediatric mid-dose cohort in the first half of 2022 and expects to initiate dosing of the pediatric high-dose cohort this year
Read more →EDITEditas Medicine Reports Engineered iNK Cell Preclinical Data at American Association for Cancer Research Annual Meeting
Preclinical data demonstrate that edited iNK cells result in increased persistence, enhanced anti-tumor activity and extended survival supporting continued development as a novel therapeutic approach for solid tumors In vivo preclinical data show that edited iNK cells in combina
Read more →EDITEditas Medicine Announces Favorable Decision from U.S. Patent and Trademark Office in CRISPR Patent Interference
CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, announced today the U.S. Patent and Trademark Office (USPTO) issued another favorable decision to the Broad Institute, Inc. (Broad) involving specific paten
Read more →EDIT▲ +10.1%on this news· ran to +21% by day 3shared move
Editas Medicine Announces Fourth Quarter and Full Year 2021 Results and Business Updates EDIT-101 Phase 1/2 BRILLIANCE trial enrolling mid-dose pediatric cohort; clinical data update expected in 2H 2022 EDIT-301 remains
Editas Medicine Announces Fourth Quarter and Full Year 2021 Results and Business Updates EDIT-101 Phase 1/2 BRILLIANCE trial enrolling mid-dose pediatric cohort; clinical data update expected in 2H 2022 EDIT-301 remains on track to dose first sickle cell disease patient in 1H 2
Read more →EDITEditas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2021 Results and Corporate Update
CAMBRIDGE, Mass., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Thursday, February 24, 2022, at 8:00 a.m. ET to provide a corporate update and results fo
Read more →EDITEditas Medicine Reports on Recent Progress and Outlook at J.P. Morgan Healthcare Conference
Anticipated 2022 milestones include initial clinical data for EDIT-301 in sickle cell disease by year-end, dosing of first TDT patient with EDIT-301, initiation of pediatric high-dose cohort for EDIT-101 in LCA10, and a clinical data update on EDIT-101 in the second half of 2022
Read more →EDITEditas Medicine to Present at the 40th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will present a company overview and update at the 40th Annual J.P. Morgan Healthcare Conference, held virtually, on Wednesday, Janua
Read more →EDITEditas Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for EDIT-301 for the Treatment of Transfusion-Dependent Beta Thalassemia
EDIT-301 is in development as a transformative, one-time treatment for people living with transfusion-dependent beta thalassemia Editas Medicine will initiate a Phase 1/2 clinical trial in 2022 CAMBRIDGE, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: E
Read more →EDITEditas Medicine Reports Preclinical Data Demonstrating Robust Tumor Reduction and Clearance Using Novel, Engineered iNK Cells at the American Society of Hematology Annual Meeting
Preclinical data demonstrating Editas-engineered AsCas12a multiplexed editing of iPSCs enhances iNK tumor killing ability, supporting promise as a potential therapeutic approach for solid tumors iNKs with double knock-in of CD16 and mbIL-15 in combination with monoclonal antibod
Read more →EDITEditas Medicine Presents Preclinical Data on Novel Engineered iPSC-derived NK Cells for the Treatment of Cancer at the Society for Immunotherapy of Cancer 36th Annual Meeting
CAMBRIDGE, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced preclinical data on its progress in the development of novel engineered induced pluripotent stem cell (iPSC)-derived natural killer (NK) cel
Read more →EDIT▲ +8.2%on this news
Editas Medicine Announces Third Quarter 2021 Results and Business Updates EDIT-101 Phase 1/2 BRILLIANCE trial initial clinical data demonstrated favorable safety profile and preliminary evidence of clinical benefit; enro
Editas Medicine Announces Third Quarter 2021 Results and Business Updates EDIT-101 Phase 1/2 BRILLIANCE trial initial clinical data demonstrated favorable safety profile and preliminary evidence of clinical benefit; enrollment ongoing in adult high-dose and pediatric mid-dose co
Read more →EDITEditas Medicine to Present Data Demonstrating Progress Towards Transformative Gene Editing Medicines for the Treatment of Hemoglobinopathies and Cancer at the ASH Annual Meeting and Exposition
EDIT-301 preclinical data support differentiated approach to develop a transformative medicine for people living with transfusion-dependent beta thalassemia Preclinical data demonstrating proprietary CRISPR/Cas12a multiplexed editing of iPSCs enhances iNK tumor killing ability,
Read more →EDITEditas Medicine Names Bernadette Connaughton to Board of Directors
CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it has appointed Bernadette Connaughton to its Board of Directors. Ms. Connaughton is an accomplished pharmaceutical executive with mo
Read more →EDITEditas Medicine to Host Conference Call Discussing Third Quarter 2021 Results and Corporate Update
CAMBRIDGE, Mass., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Monday, November 8, 2021, at 8:00 a.m. ET to provide a corporate update and results for t
Read more →EDITEditas Medicine to Present Preclinical Data on Novel Engineered iPSC Derived NK Cells for the Treatment of Cancer at the Society for Immunotherapy of Cancer 36th Annual Meeting
CAMBRIDGE, Mass., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that the Company will present preclinical data on its progress in the development of cell therapy medicines for the treatment of cancer at t
Read more →EDITEditas Medicine to Present at Chardan’s 5th Annual Genetic Medicines Conference
CAMBRIDGE, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, will present at Chardan’s 5th Annual Genetic Medicines Conference on Monday, October 4, 2021 at 8:30 a.m. ET. A live webcast of the presentation will be a
Read more →EDIT▼ -19%on this newsshared move
Editas Medicine Announces Positive Initial Clinical Data from Ongoing Phase 1/2 BRILLIANCE Clinical Trial of EDIT-101 for LCA10 No serious adverse events or dose-limiting toxicities observed to date Efficacy signals in t
Editas Medicine Announces Positive Initial Clinical Data from Ongoing Phase 1/2 BRILLIANCE Clinical Trial of EDIT-101 for LCA10 No serious adverse events or dose-limiting toxicities observed to date Efficacy signals in the mid-dose cohort provide initial support for clinical be
Read more →EDITEditas Medicine Names Emma Reeve to Board of Directors
CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that it has appointed Emma Reeve to its Board of Directors. Ms. Reeve is an accomplished biopharmaceutical executive with more than 25 yea
Read more →EDITEditas Medicine Presents Data on New SLEEK Gene Editing Technology at Cold Spring Harbor Laboratory’s Genome Engineering: CRISPR Frontiers Meeting
SLEEK enables high efficiency, multi-transgene knock-in of induced Pluripotent Stem Cells (iPSCs), T cells, and Natural Killer (NK) cells Data support SLEEK as an optimized approach to develop next generation cell therapy medicines CAMBRIDGE, Mass., Aug. 20, 2021 (GLOBE NEWSWIR
Read more →EDIT▲ +9.4%on this news· ran to +38% by day 3
Editas Medicine Announces Second Quarter 2021 Results and Business Updates Enrolling first pediatric and adult high dose cohorts of EDIT-101 BRILLIANCE trial for LCA10 EDIT-101 initial clinical data planned for September
Editas Medicine Announces Second Quarter 2021 Results and Business Updates Enrolling first pediatric and adult high dose cohorts of EDIT-101 BRILLIANCE trial for LCA10 EDIT-101 initial clinical data planned for September 2021 EDIT-301 RUBY trial for sickle cell disease screeni
Read more →EDITEditas Medicine and IDT Announce Publication in Nature Communications of Research Data Supporting the Use of Optimized AsCas12a Nuclease Variant, Alt-R A.s. Cas12a (Cpf1) Ultra, in Researching the Potential of Gene-Edited Cell Medicines
CAMBRIDGE, Mass. and CORALVILLE, Iowa, July 29, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, and Integrated DNA Technologies, Inc. (IDT), a leading comprehensive genomics research solutions provider, today announced the publicat
Read more →EDIT▲ +6.4%on this newsshared move
Editas Medicine to Host Conference Call Discussing Second Quarter 2021 Results and Corporate Update
CAMBRIDGE, Mass., July 28, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Wednesday, August 4, 2021, at 8:00 a.m. ET to provide a corporate update and results for
Read more →EDITEditas Medicine Names Bruce E. Eaton, Ph.D., as Executive Vice President and Chief Business Officer
Dr. Eaton joined the Company in 2018 and brings more than 30 years of experience to the role CAMBRIDGE, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that Bruce E. Eaton, Ph.D., has been promoted
Read more →EDITEditas Medicine Announces Enrollment of the First Pediatric Cohort in the BRILLIANCE Clinical Trial of EDIT-101 for the Treatment of LCA10 Following IDMC Endorsement
IDMC endorsed proceeding with first pediatric cohort based on a review of clinical safety data from adult low-dose and adult mid-dose cohorts Concurrently enrolling the adult high-dose cohort in the BRILLIANCE trial Company plans to report initial EDIT-101 clinical data in Sept
Read more →EDITEditas Medicine Reports Inducement Grants to New Chief Scientific Officer and Chief Regulatory Officer
CAMBRIDGE, Mass., June 15, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the grant of inducement awards to the Company’s newly appointed Executive Vice President and Chief Scientific Officer, Mark Shearman, Ph.D.,
Read more →EDITEditas Medicine Strengthens Executive Leadership Team to Advance Pipeline and Support Long-term Growth
Mark S. Shearman, Ph.D., joins as Chief Scientific Officer Chi Li, Ph.D., MBA, RAC, joins as Chief Regulatory Officer CAMBRIDGE, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it named Chi Li
Read more →EDITEditas Medicine Presents Preclinical Data Supporting the Initiation of the EDIT-301 Phase 1/2 RUBY Clinical Trial for the Treatment of Sickle Cell Disease at the European Hematology Association Congress
Preclinical data demonstrated robust fetal hemoglobin (HbF) induction in erythroid progeny cells with no detection of off-target editing; cells showed reduced sickling and improved rheological behavior RUBY trial of EDIT-301 for sickle cell disease active and recruiting CAMBRID
Read more →EDITEditas Medicine Announces First Quarter 2021 Results and Update Strengthening Leadership by Adding Mark S. Shearman, Ph.D., as Chief Scientific Officer Advancing BRILLIANCE trial of EDIT-101 for LCA10; clinical data expe
Editas Medicine Announces First Quarter 2021 Results and Update Strengthening Leadership by Adding Mark S. Shearman, Ph.D., as Chief Scientific Officer Advancing BRILLIANCE trial of EDIT-101 for LCA10; clinical data expected by year-end RUBY trial of EDIT-301 for sickle cell d
Read more →EDITEditas Medicine Names Mark S. Shearman, Ph.D., as Chief Scientific Officer
CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it named Mark S. Shearman, Ph.D., as the Company’s Executive Vice President and Chief Scientific Officer. Dr. Shearman will join Editas
Read more →EDITEditas Medicine to Present Preclinical Data Demonstrating Progress in Development of Gene Editing Medicines for the Treatment of Genetic Ocular Diseases at the American Society of Gene and Cell Therapy Annual Meeting
CAMBRIDGE, Mass., May 04, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced three presentations, including one from a research collaboration, at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting bei
Read more →EDITEditas Medicine to Present Preclinical Data Demonstrating Advancements in In Vivo Gene Editing Approach for the Treatment of Genetic Ocular Diseases at the Association for Research in Vision and Ophthalmology Annual Meeting
CAMBRIDGE, Mass., May 01, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that two scientific abstracts have been accepted for presentation at the Association for Research in Vision and Ophthalmology (ARVO) Annual M
Read more →EDITEditas Medicine to Host Conference Call Discussing First Quarter 2021 Results and Corporate Update
CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Wednesday, May 5, 2021, at 8:00 a.m. ET to discuss a corporate update and results for th
Read more →EDITEditas Medicine Announces Fourth Quarter and Full Year 2020 Results and Update Strengthened Leadership by Appointing James (Jim) C. Mullen as President and Chief Executive Officer, and Lisa A. Michaels, M.D., as Chief Me
Editas Medicine Announces Fourth Quarter and Full Year 2020 Results and Update Strengthened Leadership by Appointing James (Jim) C. Mullen as President and Chief Executive Officer, and Lisa A. Michaels, M.D., as Chief Medical Officer Appointed Meeta Chatterjee, Ph.D., to Board
Read more →EDITEditas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2020 Results and Corporate Update
CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Thursday, February 25, 2021, at 8:00 a.m. ET to discuss a corporate update and results fo
Read more →EDITEditas Medicine Announces Appointment of James C. Mullen as Chief Executive Officer Cindy Collins to Step Down Effective
Editas Medicine Announces Appointment of James C. Mullen as Chief Executive Officer Cindy Collins to Step Down Effective CAMBRIDGE, Mass., Feb. 8, 2021 - Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that James (Jim) C. Mullen will s
Read more →EDITEditas Medicine Announces Transition of Chief Scientific Officer
CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that its Chief Scientific Officer, Charles Albright, Ph.D., is stepping down from the Company on January 15 to pursue another opportunity. A
Read more →EDITEditas Medicine Announces the FDA has Cleared Initiation of the EDIT-301 Clinical Trial
CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the U.S. Food and Drug Administration (FDA) has cleared the initiation of the safety phase of the Company’s EDIT-301 clinical trial, and the
Read more →EDITEditas Medicine to Present at the 39th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will present a company overview at the 39th Annual J.P. Morgan Healthcare Conference, held virtually, on Wednesday, January 13, 2021
Read more →EDITEditas Medicine Names Meeta Chatterjee, Ph.D., to Board of Directors
CAMBRIDGE, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that it has appointed Meeta Chatterjee, Ph.D., to its Board of Directors. Dr. Chatterjee is an accomplished biopharmaceutical executive wit
Read more →EDITEditas Medicine Announces Submission of IND Application for EDIT-301 with the FDA
EDIT-301 is in development as a best-in-class, durable medicine for people living with sickle cell disease CAMBRIDGE, Mass., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced it submitted an Investigational
Read more →EDITEditas Medicine Announces Preclinical Data and Large-Scale Manufacturing Process for EDIT-301, in Development for the Treatment of Sickle Cell Disease and Beta-Thalassemia
Data support novel approach to develop and manufacture a best-in-class, durable medicine for people living with hemoglobinopathies IND filing for EDIT-301 planned by end of 2020 CAMBRIDGE, Mass., Dec. 05, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading
Read more →EDITEditas Medicine Reports Inducement Grants to New Chief Medical Officer
CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the grant of inducement awards to the Company’s newly appointed Executive Vice President and Chief Medical Officer, Lisa Michaels, M.D. In c
Read more →EDITEditas Medicine Appoints Lisa A. Michaels, M.D., as Chief Medical Officer
CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it named Lisa A. Michaels, M.D., as the Company’s Executive Vice President and Chief Medical Officer, effective immediately. Dr. Michae
Read more →EDITEditas Medicine to Present at Barclays Gene Editing & Gene Therapy Summit
CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will present at Barclays Gene Editing & Gene Therapy Summit on Monday, November 16 at 10:15am ET. The event will be webcast
Read more →EDITEditas Medicine Announces Third Quarter 2020 Results and Update EDIT-101 for LCA10 BRILLIANCE trial adult low-dose cohort completed EDIT-301 for sickle cell disease on track for IND filing by end of 2020 EDIT-201 for sol
Editas Medicine Announces Third Quarter 2020 Results and Update EDIT-101 for LCA10 BRILLIANCE trial adult low-dose cohort completed EDIT-301 for sickle cell disease on track for IND filing by end of 2020 EDIT-201 for solid tumors preclinical data to be presented at SITC and AS
Read more →EDITEditas Medicine to Host Conference Call Discussing Third Quarter 2020 Results and Corporate Update
CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Thursday, November 5, 2020, at 5:00 p.m. ET to discuss a corporate update and results for
Read more →EDITEditas Medicine to Participate in Upcoming Investor Conference
CAMBRIDGE, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will participate in the following upcoming investor conference: Chardan Virtual 4th Annual Genetic Medicines Conference Da
Read more →EDITEditas Medicine Announces U.S. Patent and Trademark Office Grants the Broad Institute Priority Benefit in CRISPR Interference
CAMBRIDGE, Mass., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, announced today the U.S. Patent and Trademark Office (USPTO) issued a decision in an interference between the University of California, the University of V
Read more →EDITEditas Medicine Receives Rare Pediatric Disease Designation for EDIT-301 for the Treatment of Sickle Cell Disease
CAMBRIDGE, Mass., Aug. 24, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation for EDIT-301, an experimental, autolog
Read more →EDITEditas Medicine Regains Full Global Rights to Ocular Medicines
CAMBRIDGE, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced it has regained full global rights to research, develop, manufacture, and commercialize its ocular medicines, including EDIT-101 for the tre
Read more →EDITEditas Medicine Announces Second Quarter 2020 Results and Update Regained full control of ocular medicines under new agreement with AbbVie BRILLIANCE trial for EDIT-101 on track to dose at least three patients by end of
Editas Medicine Announces Second Quarter 2020 Results and Update Regained full control of ocular medicines under new agreement with AbbVie BRILLIANCE trial for EDIT-101 on track to dose at least three patients by end of 2020 Plan to file IND for EDIT-301 for sickle cell diseas
Read more →EDITEditas Medicine Appoints Gad Berdugo as Chief Business Officer
CAMBRIDGE, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it has named Gad Berdugo as the Company’s Chief Business Officer. Mr. Berdugo will oversee the Company’s business and corporate develop
Read more →EDITEditas Medicine to Host Conference Call Discussing Second Quarter 2020 Results and Corporate Update
CAMBRIDGE, Mass., July 23, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Thursday, August 6, 2020, at 5:00 p.m. ET to discuss a corporate update and results for t
Read more →EDITEditas Medicine and Azzur Group Announce a Multi-year Agreement for EDIT-301 and EDIT-201 Manufacturing
CAMBRIDGE, Mass., and WALTHAM, Mass., July 07, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, and Azzur Cleanrooms on Demand™ (COD), an Azzur Group company, today announced the companies have entered a multi-year agreement for cur
Read more →EDITEditas Medicine Announces Closing of Offering of Common Stock and Full Exercise by Underwriter of Option to Purchase Additional Shares
CAMBRIDGE, Mass., June 26, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the closing of its previously announced underwritten offering of 6,900,000 shares of its common stock at a public offering price of $31.25 p
Read more →EDITEditas Medicine Presents Pre-Clinical Data from a Study of EDIT-301 with Sickle Patient Cells for the Potential Treatment of Sickle Cell Disease
CAMBRIDGE, Mass., June 12, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced results from a pre-clinical, proof-of-concept study of EDIT-301. EDIT-301 is being developed as a potentially best-in-class, durable medicin
Read more →EDITEditas Medicine Presents Pre-Clinical Data Supporting the use of CRISPR-Cas12a to Edit Induced Pluripotent Stem Cells for the Development of Engineered Cell Immunotherapies
CAMBRIDGE, Mass., May 15, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced results from a pre-clinical study evaluating multi-gene knockout and transgene knock-in using its proprietary engineered CRISPR-Cas12a (EngCa
Read more →EDITEditas Medicine Announces First Quarter 2020 Results and Update Patient dosing initiated in BRILLIANCE Phase 1/2 trial of EDIT-101 (AGN-151587) for LCA10 On track to file IND for EDIT-301 for sickle cell disease by end o
Editas Medicine Announces First Quarter 2020 Results and Update Patient dosing initiated in BRILLIANCE Phase 1/2 trial of EDIT-101 (AGN-151587) for LCA10 On track to file IND for EDIT-301 for sickle cell disease by end of 2020 Initiated IND-enabling studies for EDIT-201 alloge
Read more →EDITEditas Medicine to Host Conference Call Discussing First Quarter 2020 Results and Corporate Update
CAMBRIDGE, Mass., April 30, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Thursday, May 7, 2020, at 8:00 a.m. ET to discuss a corporate update and results for the
Read more →EDITEditas Medicine Initiates IND-enabling Activities for EDIT-201, an Allogeneic NK Cell Medicine for the Treatment of Solid Tumor Cancers
CAMBRIDGE, Mass., April 29, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the initiation of IND-enabling activities for EDIT-201, an allogeneic natural killer (NK) cell medicine for the treatment of solid tumor ca
Read more →EDITEditas Medicine Announces Fourth Quarter and Full Year 2019 Results and Update Announcement of first patient dosing with EDIT-101 (AGN-151587) expected in 1Q20 Plan to file IND for EDIT-301 for sickle cell disease by end
Editas Medicine Announces Fourth Quarter and Full Year 2019 Results and Update Announcement of first patient dosing with EDIT-101 (AGN-151587) expected in 1Q20 Plan to file IND for EDIT-301 for sickle cell disease by end of 2020 Research collaboration with Sandhill Therapeutic
Read more →EDITEditas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2019 Results and Corporate Update
CAMBRIDGE, Mass., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Wednesday, February 26, 2020, at 5:00 p.m. ET to discuss a corporate update and results f
Read more →EDITEditas Medicine Reports on Recent Progress at J.P. Morgan Healthcare Conference
Provides updates on advancements in in vivo and engineered cell medicine programs Details timeline to filing an IND for EDIT-301 for the treatment of sickle cell disease CAMBRIDGE, Mass., Jan. 13, 2020 (GLOBE NEWSWIRE) -- In a presentation to investors on Wednesday, January 15,
Read more →EDITEditas Medicine and Sandhill Therapeutics, Inc. Announce Collaboration to Develop Engineered Cell Medicines to Treat Cancer
CAMBRIDGE, Mass. and DALLAS, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, and Sandhill Therapeutics, Inc., a cellular immuno-oncology company, announced a strategic research collaboration, license, and option agreement
Read more →EDITEditas Medicine Reports Inducement Grants to New Chief Financial Officer
CAMBRIDGE, Mass., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the grant of inducement awards to the Company’s newly appointed Chief Financial Officer, Michelle Robertson. In connection with Ms. Robertso
Read more →EDITEditas Medicine Strengthens Executive Leadership Team to Support Long-term Growth
Michelle Robertson joins as Chief Financial Officer Manufacturing veteran Harry Gill joins in newly created role of Senior Vice President, Operations CAMBRIDGE, Mass., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, toda
Read more →EDITEditas Medicine to Present at the 38th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will present a company overview followed by a question and answer session at the 38th Annual J.P. Morgan Healthcare Conference on We
Read more →EDITEditas Medicine Announces In Vivo Proof-of-Concept Data for EDIT-301, in Development for the Treatment of Sickle Cell Disease and Beta-Thalassemia
CAMBRIDGE, Mass., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced in vivo proof-of-concept data supporting the development of EDIT-301 as a potentially best-in-class, durable medicine to treat sickle cell d
Read more →EDITEditas Medicine Announces Third Quarter 2019 Results and Update Amended Celgene collaboration to focus on engineered alpha-beta T cell medicines with a $70 million payment to Editas Medicine Appointed Judith R. Abrams, M
Editas Medicine Announces Third Quarter 2019 Results and Update Amended Celgene collaboration to focus on engineered alpha-beta T cell medicines with a $70 million payment to Editas Medicine Appointed Judith R. Abrams, M.D., as Chief Medical Officer EDIT-101 (AGN-151587) for L
Read more →EDITEditas Medicine and Celgene Corporation Amend Existing Collaboration to Develop and Commercialize Autologous and Allogeneic T Cell Medicines for the Treatment of Cancer and Autoimmune Diseases
The companies will continue to collaborate to discover and develop the next generation of engineered alpha-beta T cells Editas Medicine to receive a $70 million payment and may be eligible for future milestone and royalty payments CAMBRIDGE, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE
Read more →EDITEditas Medicine to Host Conference Call Discussing Third Quarter 2019 Results and Corporate Update
CAMBRIDGE, Mass., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Tuesday, November 12, 2019, at 8:00 a.m. ET to discuss a corporate update and results for
Read more →EDITEditas Medicine Appoints Judith R. Abrams, M.D., as Chief Medical Officer
CAMBRIDGE, Mass., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it named Judith R. Abrams, M.D., as the Company’s Chief Medical Officer, effective immediately. Dr. Abrams is a leading drug developmen
Read more →EDITEditas Medicine and AskBio Enter Strategic Research Collaboration to Explore In Vivo Delivery of Genome Editing Medicines to Treat Neurological Diseases
CAMBRIDGE, Mass. and RESEARCH TRIANGLE PARK, N.C., Oct. 15, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, and Asklepios BioPharmaceutical, Inc. (AskBio), a fully integrated adeno-associated virus (AAV) gene therapy company, today
Read more →EDITEditas Medicine and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Cell Medicines
CAMBRIDGE, Mass. and GAITHERSBURG, Md., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, and MaxCyte, Inc., the global cell-based therapies and life sciences company, today announced a new clinical and commercial license ag
Read more →EDITEditas Medicine Appoints Cynthia Collins as President and Chief Executive Officer
CAMBRIDGE, Mass., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that its Board of Directors has unanimously appointed Cynthia (Cindy) Collins, a 30-plus year industry veteran currently serving as the Comp
Read more →EDITEditas Medicine Announces Second Quarter 2019 Results and Update Cynthia (Cindy) Collins named President and Chief Executive Officer Initiated Brilliance Phase 1/2 clinical trial of EDIT-101(AGN-151587) for LCA10 Patient
Editas Medicine Announces Second Quarter 2019 Results and Update Cynthia (Cindy) Collins named President and Chief Executive Officer Initiated Brilliance Phase 1/2 clinical trial of EDIT-101(AGN-151587) for LCA10 Patient dosing in Brilliance trial on track for 2H19 EDIT-301 f
Read more →EDITEditas Medicine to Host Conference Call Discussing Second Quarter 2019 Results and Corporate Update
CAMBRIDGE, Mass., July 30, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Tuesday, August 6, 2019, at 5:00 p.m. ET to discuss a corporate update and results for th
Read more →EDITEditas Medicine Presents Pre-Clinical Data for Treatment of Sickle Cell Disease and Beta-Thalassemia at the 24th Congress of the European Hematology Association
IND-enabling activities initiated for EDIT-301, a potentially best-in-class experimental medicine for the treatment of sickle cell disease and beta-thalassemia CAMBRIDGE, Mass., June 15, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing comp
Read more →EDITEditas Medicine Announces First Quarter 2019 Results and Update - Building on focus in oncology through newly-formed partnership with BlueRock Therapeutics to develop universal allogeneic cell medicines for cancer - - ED
Editas Medicine Announces First Quarter 2019 Results and Update - Building on focus in oncology through newly-formed partnership with BlueRock Therapeutics to develop universal allogeneic cell medicines for cancer - - EDIT-101 (AGN-151587) for LCA10 on track for first patient d
Read more →EDITEditas Medicine to Host Conference Call Discussing First Quarter 2019 Results and Corporate Update
CAMBRIDGE, Mass., April 30, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Tuesday, May 7, 2019, at 5:00 p.m. ET to discuss a corporate update and results for the
Read more →EDITEditas Medicine and BlueRock Therapeutics Enter Strategic Research Collaboration and Cross-Licensing Agreement to Combine Genome Editing and Cell Therapy Platforms
– Collaboration enables BlueRock to discover and develop engineered cell medicines broadly across neurology, cardiology and immunology – – Collaboration enables Editas Medicine to discover and develop engineered cell medicines across oncology, including solid tumors and blood ca
Read more →EDITEditas Medicine Announces Fourth Quarter and Full Year 2018 Results and Update EDIT 101 for LCA10 set to be first ever in vivo CRISPR medicine administered to patients with dosing expected in second half of 2019 Advancin
Editas Medicine Announces Fourth Quarter and Full Year 2018 Results and Update EDIT 101 for LCA10 set to be first ever in vivo CRISPR medicine administered to patients with dosing expected in second half of 2019 Advancing potentially best-in-class engineered cell medicine for
Read more →EDITEditas Medicine Supports Global Movement to Raise Awareness on Rare Disease Day
CAMBRIDGE, Mass., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, announced today the Company is joining forces with the nearly 30 million Americans living with a rare disease and health care advocates around the world to
Read more →EDITEditas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2018 Corporate Update and Results
CAMBRIDGE, Mass., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Thursday, February 28, 2019, at 5:00 p.m. ET to discuss a corporate update and results fo
Read more →EDITEditas Medicine Names David Scadden, M.D., to Board of Directors
CAMBRIDGE, Mass., Feb. 06, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that it has appointed David T. Scadden, M.D., to its Board of Directors, effective immediately. Dr. Scadden is a hematologist/oncologist an
Read more →EDITEditas Medicine Announces Chief Executive Officer Transition Katrine Bosley to Step Down as President and CEO Director Cynthia Collins to Serve as Interim CEO Board of Directors Initiates Search for Permanent Successor
Editas Medicine Announces Chief Executive Officer Transition Katrine Bosley to Step Down as President and CEO Director Cynthia Collins to Serve as Interim CEO Board of Directors Initiates Search for Permanent Successor CAMBRIDGE, Mass., Jan. 22, 2019 Editas Medicine, Inc. (NA
Read more →EDITEditas Medicine Announces Publication in Nature Medicine of Data Supporting the Development of EDIT-101 to Treat Leber Congenital Amaurosis 10 (LCA10)
CAMBRIDGE, Mass., Jan. 21, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the journal Nature Medicine published the comprehensive, pre-clinical data demonstrating the pharmacology and specificity of EDIT-101, an ex
Read more →EDITEditas Medicine to Present at the 37th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present a company overview followed by a question and answer session at the 37th Annual J.P. Morgan Healthcare Conference on Wed
Read more →EDITEditas Medicine Announces Transition of Chief Financial Officer
CAMBRIDGE, Mass., Dec. 21, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that its Chief Financial Officer, Andrew Hack, M.D., Ph.D., will be stepping down from the Company, effective March 1, 2019, to return to th
Read more →EDITEditas Medicine Names Cynthia Collins to Board of Directors
CAMBRIDGE, Mass., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it has appointed Cynthia Collins to its Board of Directors. Ms. Collins is a recognized leader in cell and gene therapy, molecular dia
Read more →EDITEditas Medicine Announces Pre-Clinical Data Supporting Novel Approach for Treatment of Sickle Cell Disease and Beta-Thalassemia
CAMBRIDGE, Mass., Dec. 02, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced results from experiments to demonstrate expanded CRISPR genome editing strategies in hematopoietic stem cells for the treatment of sickle ce
Read more →EDITEditas Medicine Announces FDA Acceptance of IND Application for EDIT-101
EDIT-101 set to be the first in vivo CRISPR medicine administered to people anywhere in the world Earns $25 million milestone for IND acceptance from partner Allergan CAMBRIDGE, Mass., Nov. 30, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome edi
Read more →EDITEditas Medicine Announces Third Quarter 2018 Results and Update Filed IND application for EDIT-101 with FDA in October Favorable Appeals Court ruling affirms strength of foundational intellectual property Oral presentati
Editas Medicine Announces Third Quarter 2018 Results and Update Filed IND application for EDIT-101 with FDA in October Favorable Appeals Court ruling affirms strength of foundational intellectual property Oral presentation at ASH Annual Meeting to highlight novel Sickle Cell D
Read more →EDITEditas Medicine to Host Conference Call Discussing Third Quarter 2018 Corporate Update and Results
CAMBRIDGE, Mass., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Wednesday, November 7, 2018, at 5:00 p.m. ET to discuss a corporate update and results for
Read more →EDITEditas Medicine Grows Scientific Leadership with Two New Appointments
CAMBRIDGE, Mass., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that Richard A. Morgan, Ph.D., a leading expert in gene therapy and oncology, joins the Company as Senior Vice President of Immunogenetics.
Read more →EDITEditas Medicine Announces U.S. Court of Appeals for the Federal Circuit Affirms Favorable U.S. Patent and Trademark Office Decision in CRISPR Interference
CAMBRIDGE, Mass., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, announced today that the U.S. Court of Appeals for the Federal Circuit (CAFC) affirmed the U.S. Patent and Trademark Office (USPTO) decision that ended the
Read more →EDITEditas Medicine Announces Transition of Chief Medical Officer
CAMBRIDGE, Mass., Aug. 27, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that its Chief Medical Officer, Gerald Cox, M.D., Ph.D., will be stepping down from the Company at the end of the year. A search is underway
Read more →EDITEditas Medicine Announces the Completion of the Recombinant DNA Advisory Committee (RAC) Registration Process
CAMBRIDGE, Mass., Aug. 16, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, announced today the National Institutes of Health (NIH) Recombinant DNA Advisory Committee (RAC) completed the NIH protocol registration process for EDIT-10
Read more →EDITEditas Medicine Announces Second Quarter 2018 Results and Update Allergan exercises option to develop and commercialize EDIT 101 globally and Editas exercises option to co-develop and equally share profits and losses in
Editas Medicine Announces Second Quarter 2018 Results and Update Allergan exercises option to develop and commercialize EDIT 101 globally and Editas exercises option to co-develop and equally share profits and losses in the United States Plan to file EDIT 101 Investigational Ne
Read more →EDITEditas Medicine to Host Conference Call Discussing Second Quarter 2018 Corporate Update and Results
CAMBRIDGE, Mass., July 30, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Monday, August 6, 2018, at 5:00 p.m. ET to discuss a corporate update and results for the
Read more →EDITEditas Medicine to Participate in The JMP Securities Life Sciences Conference
CAMBRIDGE, Mass., June 13, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will participate in a panel and host investor meetings at the JMP Securities Life Sciences Conference in New York on Wednesday, June
Read more →EDITEditas Medicine Reports Data Demonstrating Subretinal Injection of EDIT-101 Well-tolerated in Non-human Primates
CAMBRIDGE, Mass., May 18, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced results from a pre-clinical study demonstrating that EDIT-101 was well-tolerated when administered to non-human primates (NHP) via subretinal
Read more →EDITEditas Medicine to Present at the Bank of America Merrill Lynch 2018 Health Care Conference
CAMBRIDGE, Mass., May 08, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will participate in a fireside chat at the Bank of America Merrill Lynch 2018 Health Care Conference on Tuesday, May 15, 2018, at 8 a.
Read more →EDITEditas Medicine Announces First Quarter 2018 Results and Update Expanded Celgene collaboration to drive lead oncology program in solid tumors Strengthened Board of Directors with addition of James C. Mullen and Jessica H
Editas Medicine Announces First Quarter 2018 Results and Update Expanded Celgene collaboration to drive lead oncology program in solid tumors Strengthened Board of Directors with addition of James C. Mullen and Jessica Hopfield, Ph.D. Cash, cash equivalents, and marketable sec
Read more →EDITEditas Medicine to Present New Data Demonstrating Progress Towards Creating Genome Editing Medicines at the American Society of Gene & Cell Therapy Annual Meeting
CAMBRIDGE, Mass., April 30, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that 10 scientific abstracts, including three from research collaborations, have been accepted for presentation at the 21st Annual Meeting o
Read more →EDITEditas Medicine to Host Conference Call Discussing First Quarter 2018 Corporate Update and Results
CAMBRIDGE, Mass., April 26, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Thursday, May 3, 2018, at 5:00 p.m. ET to discuss a corporate update and results for the
Read more →EDITEditas Medicine Names James C. Mullen as Chairman of the Board of Directors
CAMBRIDGE, Mass., March 28, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the appointment of James C. Mullen as Chairman of the Board of Directors, effective immediately. Mr. Mullen has more than 30 years of exper
Read more →EDITEditas Medicine Announces Fourth Quarter and Full Year 2017 Results and Update EDIT-101 for Leber Congenital Amaurosis type 10 (LCA10) on track for mid-2018 Investigational New Drug (IND) filing Expecting at least five c
Editas Medicine Announces Fourth Quarter and Full Year 2017 Results and Update EDIT-101 for Leber Congenital Amaurosis type 10 (LCA10) on track for mid-2018 Investigational New Drug (IND) filing Expecting at least five clinical-stage programs by end of 2022 as part of EM22 five
Read more →EDITEditas Medicine Supports Rare Disease Day and Joins Global Movement to Raise Important Awareness for Rare Diseases
CAMBRIDGE, Mass., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the Company has joined forces with 30 million Americans and health care advocates around the world for Rare Disease Day® today. Rare Disease
Read more →EDITEditas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2017 Corporate Update and Results
CAMBRIDGE, Mass., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Tuesday, March 6th, 2018, at 5:00 p.m. ET to discuss a corporate update and results for th
Read more →EDITEditas Medicine Names Jessica Hopfield, Ph.D., to Board of Directors
CAMBRIDGE, Mass., Feb. 16, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the appointment of Jessica Hopfield, Ph.D., to its Board of Directors, effective immediately. Dr. Hopfield will also serve on the Audit Commi
Read more →EDITEditas Medicine Reports on Recent Progress and Announces “EM22” Five-year Goals at J.P. Morgan Healthcare Conference
By the end of 2022, Company expects to have three experimental medicines in early-stage clinical trials and two experimental medicines in or ready for late-stage clinical trials Announces first acquisition with purchase of certain assets from i2 Pharmaceuticals and its affiliate
Read more →EDITEditas Medicine to Present at the 36th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present a company overview followed by a question and answer session at the 36th Annual J.P. Morgan Healthcare Conference on Wed
Read more →EDITEditas Medicine Reports Data Supporting Multiple Approaches to Create Treatments for Sickle Cell Disease and Beta-Thalassemia
CAMBRIDGE, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced results from experiments to demonstrate expanded CRISPR genome editing strategies in hematopoietic stem cells for the treatment of hematologi
Read more →EDITEditas Medicine, Inc., Announces Pricing of $50 Million Offering of Common Stock
CAMBRIDGE, Mass., Dec. 06, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the pricing of an underwritten offering of 1,970,000 shares of its common stock. The gross proceeds to Editas Medicine from this offering are
Read more →EDITEditas Medicine, Inc., Announces Offering of Common Stock
Editas Medicine, Inc., Announces Offering of Common Stock CAMBRIDGE, Mass., December 5, 2017 Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that it intends to offer and sell $50,000,000 of shares of its common stock in an underwritten pub
Read more →EDITEditas Medicine Announces Third Quarter 2017 Results and Update
Editas Medicine Announces Third Quarter 2017 Results and Update CAMBRIDGE, Mass., November 7, 2017 (GLOBE NEWSWIRE) Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today reported financial results for the third quarter ended September 30, 2017, and provid
Read more →EDITEditas Medicine to Host Conference Call Discussing Third Quarter 2017 Corporate Update and Results
CAMBRIDGE, Mass., Nov. 03, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Tuesday, November 7, 2017, at 5:00 p.m. ET to discuss a corporate update and results for t
Read more →EDITEditas Medicine Demonstrates Dose-Dependent, In Vivo Editing with EDIT-101 in CEP290 Transgenic Mice
CAMBRIDGE, Mass., Oct. 19, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced results from a pre-clinical study in transgenic mice demonstrating dose-dependent, in vivo editing using EDIT-101, Editas Medicine’s pre-clin
Read more →EDITEditas Medicine to Participate in Investor Conferences in October
CAMBRIDGE, Mass., Oct. 03, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will participate in two upcoming investor conferences in New York in October. Details are as follows: Chardan Gene Therapy
Read more →EDITEditas Medicine Receives EMA’s Orphan Medicinal Product Designation for EDIT-101 for the Treatment of LCA10
CAMBRIDGE, Mass., Sept. 26, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the European Medicines Agency (EMA) granted Orphan Medicinal Product designation to EDIT-101, a pre-clinical, CRISPR-based medicinal product
Read more →EDITEditas Medicine Initiates Clinical Natural History Study to Evaluate Patients with Leber Congenital Amaurosis Type 10 (LCA10)
CAMBRIDGE, Mass., Sept. 12, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that the Company initiated a clinical natural history study of Leber Congenital Amaurosis type 10 (LCA10). LCA10 is caused by mutations in t
Read more →EDITEditas Medicine to Participate in Morgan Stanley 15th Annual Global Healthcare Conference
CAMBRIDGE, Mass., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will participate in a fireside chat at the Morgan Stanley 15th Annual Global Healthcare Conference on Tuesday, September 12,
Read more →EDITEditas Medicine Achieves Milestone Under Juno Therapeutics Collaboration for Technical Progress Towards Overcoming the Tumor Microenvironment
CAMBRIDGE, Mass., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, announced today that it achieved a second milestone under its collaboration with Juno Therapeutics, Inc. (NASDAQ:JUNO). The most recent milestone results fro
Read more →EDITEditas Medicine Announces Second Quarter 2017 Results and Update Leber Congenital Amaurosis type 10 (LCA10) product candidate EDIT 101 made significant progress toward clinical trials Achieved research milestone in Juno
Editas Medicine Announces Second Quarter 2017 Results and Update Leber Congenital Amaurosis type 10 (LCA10) product candidate EDIT 101 made significant progress toward clinical trials Achieved research milestone in Juno Therapeutics, Inc., collaboration CAMBRIDGE, Mass., Augus
Read more →EDITEditas Medicine to Host Conference Call Discussing Second Quarter 2017 Corporate Update and Results
CAMBRIDGE, Mass., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Wednesday, August 9th, 2017, at 5:00 p.m. ET to discuss a corporate update and results for
Read more →EDITEditas Medicine to Participate in Investor Conferences in June
CAMBRIDGE, Mass., June 13, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will participate in two upcoming investor conferences in June. Details are as follows: JMP Securities Life Sciences Confere
Read more →EDITEditas Medicine Names Andrew Hirsch to Board of Directors
CAMBRIDGE, Mass., May 31, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the appointment of Andrew Hirsch to its board of directors, effective immediately. Mr. Hirsch will also serve as chairman of the audit committ
Read more →EDITEditas Medicine Announces First Quarter 2017 Results and Update Entered strategic R&D alliance with ophthalmology leader Allergan to develop and commercialize ground-breaking medicines for patients with serious eye disea
Editas Medicine Announces First Quarter 2017 Results and Update Entered strategic R&D alliance with ophthalmology leader Allergan to develop and commercialize ground-breaking medicines for patients with serious eye diseases Completed successful follow-on offering of common stoc
Read more →EDITEditas Medicine Demonstrates First Achievement of In Vivo Editing in Non-human Primate Retinas
CAMBRIDGE, Mass., May 13, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced results from a pre-clinical study demonstrating the first achievement of efficient editing of the CEP290 gene in the retina of non-human prima
Read more →EDITEditas Medicine Announces Pre-Clinical Data for Program to Treat Sickle Cell Disease and Beta-Thalassemia
CAMBRIDGE, Mass., May 11, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced results from its pre-clinical hematopoietic stem cell (HSC) program confirming the potential for CRISPR-based editing to treat sickle cell dis
Read more →EDITEditas Medicine to Present at Investor Conferences in May
CAMBRIDGE, Mass., May 08, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will participate in two upcoming investor conferences in May. Details are as follows: Bank of America Merrill Lynch 2017 Heal
Read more →EDITEditas Medicine to Host Conference Call Discussing First Quarter 2017 Corporate Update and Results
CAMBRIDGE, Mass., May 08, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Monday, May 15, 2017, at 5:00 p.m. ET to discuss a corporate update and results for the fir
Read more →EDITEditas Medicine to Present New Data Demonstrating Advancements for Translating CRISPR Technologies into Medicines at the American Society of Gene & Cell Therapy Annual Meeting
Oral presentation of first achievement of in vivo retinal gene editing in non-human primates Oral presentation of results demonstrating the potential of CRISPR/Cas9 gene editing to treat sickle cell disease and beta-thalassemia CAMBRIDGE, Mass., April 24, 2017 (GLOBE NEWSWIRE)
Read more →EDITEditas Medicine, Inc. (Nasdaq: EDIT) to Ring The Nasdaq Stock Market Opening Bell
ADVISORY, April 24, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq:EDIT), a leading genome editing company, will visit the Nasdaq MarketSite in Times Square. In honor of the occasion, Katrine Bosley, Chief Executive Officer, will ring the Opening Bell. Nasdaq MarketSit
Read more →EDITEditas Medicine, Inc., Announces Pricing of $90 Million Offering of Common Stock
Editas Medicine, Inc., Announces Pricing of $90 Million Offering of Common Stock CAMBRIDGE, Mass., March 16, 2017 Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced the pricing of an underwritten offering of 4,000,000 shares of its common sto
Read more →EDITEditas Medicine, Inc., Announces Proposed Offering of Common Stock
CAMBRIDGE, Mass., March 15, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it intends to offer and sell 4,000,000 shares of its common stock in an underwritten public offering. Editas Medicine intends to grant
Read more →EDITEditas Medicine Announces Fourth Quarter and Full Year 2016 Results and Update
Editas Medicine Announces Fourth Quarter and Full Year 2016 Results and Update Recent, highly favorable U.S. Patent and Trademark Office decision affirms and upholds fundamental CRISPR/Cas9 issued patents Extended CRISPR technology leadership with addition of novel and differen
Read more →EDITEditas Medicine Announces Departure of Chief Operating Officer
CAMBRIDGE, Mass., March 03, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that its Chief Operating Officer, Alexandra Glucksmann, Ph.D., will be leaving the Company, effective March 31. Dr. Glucksmann’s responsibil
Read more →EDITEditas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2016 Corporate Update and Results
CAMBRIDGE, Mass., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Tuesday, March 7, 2017, at 5:00 p.m. ET to discuss a corporate update and results for the
Read more →EDITEditas Medicine Joins Global Movement to Raise Awareness on Rare Disease Day 2017
CAMBRIDGE, Mass., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, announced the company has joined forces with 30 million Americans and health care advocates around the world today for Rare Disease Day®. Rare Disease Day is
Read more →EDITEditas Medicine to Present at Investor Conferences in March
CAMBRIDGE, Mass., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will participate in two upcoming investor conferences in March. Details of the presentations are as follows: Cowen & Company
Read more →EDITEditas Medicine Announces U.S. Patent and Trademark Office Decision Favorable to Broad Institute in CRISPR Interference
CAMBRIDGE, Mass., Feb. 15, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT) announced today that the U.S. Patent and Trademark Office (USPTO) issued a favorable decision in the CRISPR interference between the University of California, the University of Vienna, Emmanue
Read more →EDITEditas Medicine to Present at Upcoming February Investor Conferences
CAMBRIDGE, Mass., Feb. 10, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will present a company overview at two upcoming investor conferences in February. Details of the presentations are as follows
Read more →EDITEditas Medicine Reports on Recent Progress and 2017 Goals at J.P. Morgan Healthcare Conference
- Company Achieves In Vivo Proof-of-Editing in the Retina of Non-Human Primates - - Unparalleled Genome Editing Platform Includes Cpf1 and Advanced Forms of Cas9 - CAMBRIDGE, Mass., Jan. 09, 2017 (GLOBE NEWSWIRE) -- In a presentation to investors on Wednesday, January 11, 2017
Read more →EDITEditas Medicine to Present at the 35th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present a company overview followed by a question and answer session at the 35th Annual J.P. Morgan Healthcare Conference on Wed
Read more →EDITEditas Medicine Extends CRISPR Genome Editing Leadership Through Licensing of New CRISPR Technologies
-- Company to Receive Global Licenses for Novel CRISPR System Cpf1 and Advanced Forms of Cas9 -- CAMBRIDGE, Mass., Dec. 19, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced it has exclusively licensed intellectual pr
Read more →EDITEditas Medicine to Present at the Stifel Healthcare Conference 2016
CAMBRIDGE, Mass., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present a company overview at the Stifel Healthcare Conference 2016 on Wednesday, November 16, 2016, at 10:15 a.m. ET in New Yor
Read more →EDITEditas Medicine Announces Third Quarter 2016 Results and Update
Editas Medicine Announces Third Quarter 2016 Results and Update Further strengthened leadership team with appointments of Charles Albright, Ph.D., as Chief Scientific Officer, and Gerald Cox, M.D., Ph.D., as Chief Medical Officer CAMBRIDGE, Mass., November 7, 2016 Editas Medici
Read more →EDITEditas Medicine to Host Conference Call Discussing Third Quarter 2016 Corporate Update and Results
CAMBRIDGE, Mass., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Monday, November 7, 2016, at 5:00 p.m. ET to discuss a corporate update and results for th
Read more →EDITEditas Medicine to Present Data on CRISPR/Cas9-mediated Gene Editing in Hematopoietic Stem/Progenitor Cells at ESGCT-ISSCR 2016
CAMBRIDGE, Mass., Oct. 17, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that its scientists will present data on the use of CRISPR/Cas9-mediated gene editing in human hematopoietic stem/progenitor cells in a poste
Read more →EDITEditas Medicine to Present at the Jefferies Gene Editing/Therapy Summit
CAMBRIDGE, Mass., Oct. 03, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, announced today that it will present at 9:00 a.m. ET and participate in a panel discussion at 10:00 a.m. ET at the Jefferies Gene Editing/Therapy Summit on T
Read more →EDITEditas Medicine Expands Senior Management Team
-- Appoints Gerald Cox, M.D., Ph.D., as Chief Medical Officer -- -- Kenneth LeClair, Ph.D. joins as Vice President, Technical Development and Manufacturing and Semiramis Trotto joins as Vice President, Human Resources -- CAMBRIDGE, Mass., Oct. 03, 2016 (GLOBE NEWSWIRE) -- Edita
Read more →EDITEditas Medicine to Present at the Morgan Stanley Global Healthcare Conference
CAMBRIDGE, Mass., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 14, 2016 at 9:55 a.m. ET in New York City.
Read more →EDITSUBLEASE AMENDMENT NO. 1 This Sublease Amendment No. 1 (this “Amendment”) is made as of this 31st day of August, 2016 by and between ALNYLAM PHARMACEUTICALS, INC., a Delaware corporation (“Sublessor&
SUBLEASE AMENDMENT NO. 1 This Sublease Amendment No. 1 (this Amendment ) is made as of this 31st day of August, 2016 by and between ALNYLAM PHARMACEUTICALS, INC., a Delaware corporation ( Sublessor ) and EDITAS MEDICINE, INC., a Delaware corporation ( Sublessee ). WHEREAS, Subl
Read more →EDITEditas Medicine Names Charles Albright as Chief Scientific Officer
CAMBRIDGE, Mass., Aug. 22, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, announced today the appointment of Charles Albright, Ph.D. as Chief Scientific Officer. Dr. Albright brings to Editas more than 25 years of life sciences ind
Read more →EDITEditas Medicine Announces Second Quarter 2016 Results and Update Exclusive license to high-fidelity Cas9 and Cas9 PAM variants from Massachusetts General Hospital further advances leading genome editing platform Strategi
Editas Medicine Announces Second Quarter 2016 Results and Update Exclusive license to high-fidelity Cas9 and Cas9 PAM variants from Massachusetts General Hospital further advances leading genome editing platform Strategic partnership with Adverum to explore delivery of genomic
Read more →EDITEditas Medicine Announces Exclusive License to Advanced CRISPR Genome Editing Technology from Massachusetts General Hospital
-- License to Engineered Forms of Cas9 Nuclease Includes High-Fidelity Cas9 and Cas9 PAM Variants -- CAMBRIDGE, Mass., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the Company has entered into an exclusi
Read more →EDITEditas Medicine to Host Conference Call Discussing Second Quarter 2016 Corporate Update and Results
CAMBRIDGE, Mass., Aug. 02, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Tuesday, August 9, 2016, at 5:00 p.m. ET to discuss a corporate update and results for the
Read more →EDITEditas Medicine Appoints Akshay Vaishnaw, M.D., Ph.D., to its Board of Directors
CAMBRIDGE, Mass., July 29, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, announced today the appointment of Akshay Vaishnaw, M.D., Ph.D., to its board of directors. Dr. Vaishnaw is Executive Vice President of Research and Developm
Read more →EDITEditas Medicine Announces Scientific Multi-Year Collaboration with Fondazione Telethon and Ospedale San Raffaele
CAMBRIDGE, Mass., July 28, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, and Fondazione Telethon and Ospedale San Raffaele, which operate a joint research collaboration known as the San Raffaele Telethon Institute for Gene Therapy
Read more →EDITEditas Medicine to Present at Upcoming June Investor Conferences
CAMBRIDGE, Mass., May 24, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present company overviews at three upcoming investor conferences in June: Goldman Sachs 37th Annual Global Healthcare Conference
Read more →EDITEditas Medicine Announces Agreement with Cystic Fibrosis Foundation Therapeutics to Advance New CRISPR/Cas9 Medicines
CAMBRIDGE, Mass., May 16, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced a three-year agreement with Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the nonprofit affiliate of the Cystic Fibrosis Foundation, i
Read more →EDITEditas Medicine Announces First Quarter 2016 Results and Update Advancing pipeline and platform demonstrated by data presented at medical and scientific conferences as well as achievement of Juno Therapeutics milestone S
Editas Medicine Announces First Quarter 2016 Results and Update Advancing pipeline and platform demonstrated by data presented at medical and scientific conferences as well as achievement of Juno Therapeutics milestone Strengthened effort to develop medicines for cystic fibrosi
Read more →EDITEditas Medicine to Host Conference Call Discussing First Quarter 2016 Corporate Update and Results
CAMBRIDGE, Mass., May 09, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Monday, May 16, 2016 at 8:30 a.m. ET to discuss a corporate update and results for the firs
Read more →EDITEditas Medicine Achieves Milestone under its Collaboration with Juno Therapeutics
CAMBRIDGE, Mass., May 04, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, announced today that it has achieved a $2.5 million milestone under its collaboration with Juno Therapeutics, Inc. (NASDAQ:JUNO) for technical progress in a r
Read more →EDITEditas Medicine Announces Presentations at Upcoming Scientific Conferences
CAMBRIDGE, Mass., April 27, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that Editas scientists will present data from its cancer, hematology, ophthalmology and neuromuscular disease programs at the 19th Annual Me
Read more →EDITEditas Medicine to Present at Deutsche Bank 41st Annual Health Care Conference
CAMBRIDGE, Mass., April 27, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present a company overview at the Deutsche Bank 41st Annual Health Care Conference on Wednesday, May 4, 2016 at 10:40 a.m. ET i
Read more →EDITEditas Medicine to Present at 15th Annual Needham Healthcare Conference
CAMBRIDGE, Mass., April 06, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present a company overview at the 15th Annual Needham Healthcare Conference on Wednesday, April 13, 2016 at 4:20 p.m. ET in New
Read more →EDITEditas Medicine Reports Fourth Quarter and Full Year 2015 Financial Results Well-positioned to advance multiple programs and continue expansion of genome editing platform Cash balance of approximately $230 million funds
Editas Medicine Reports Fourth Quarter and Full Year 2015 Financial Results Well-positioned to advance multiple programs and continue expansion of genome editing platform Cash balance of approximately $230 million funds diversified pipeline Executive team and board of directo
Read more →EDITEditas Medicine to Present at Cowen and Company 36th Annual Health Care Conference
CAMBRIDGE, Mass., March 01, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present a company overview at the Cowen and Company 36th Annual Health Care Conference on Tuesday, March 8, 2016 at 8:40 a.m. E
Read more →EDITHurley Street, Cambridge, MA/Editas Medicine, Inc. LEASE AGREEMENT THIS LEASE AGREEMENT is made as of this 12th day of February, 2016 between ARE-MA REGION NO. 55 EXCHANGE HOLDING LLC, a Massachusetts limited liability c
11 Hurley Street, Cambridge, MA/Editas Medicine, Inc. THIS LEASE AGREEMENT is made as of this 12th day of February, 2016 between ARE-MA REGION NO. 55 EXCHANGE HOLDING LLC, a Massachusetts limited liability company ( Landlord ), and EDITAS MEDICINE, INC., a Delaware corporation (
Read more →EDITEditas Medicine Announces Closing of Initial Public Offering and Full Exercise of Option to Purchase Additional Shares
CAMBRIDGE, Mass., Feb. 08, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT) today announced the closing of its initial public offering of 6,785,000 shares of its common stock at a public offering price of $16.00 per share, before underwriting discounts and commissions
Read more →EDITEditas Medicine Announces Pricing of Initial Public Offering
CAMBRIDGE, Mass., Feb. 02, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc., a leading genome editing company, today announced the pricing of its initial public offering of 5,900,000 shares of common stock at a public offering price of $16.00 per share, before underwriting discount
Read more →Competitive Position
How EDIT ranks across every disease it competes inCompetitive Position is a premium feature
See how EDIT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial